



# OCT2 pre-positioning facilitates cell fate transition and chromatin architecture changes in humoral immunity

Ashley S. Doane<sup>1,2</sup>, Chi-Shuen Chu<sup>3</sup>, Dafne Campigli Di Giammartino<sup>4</sup>, Martín A. Rivas<sup>4</sup>, Johannes C. Hellmuth<sup>4</sup>, Yanwen Jiang<sup>1,4</sup>, Nevin Yusufova<sup>4</sup>, Alicia Alonso<sup>4</sup>, Robert G. Roeder<sup>3</sup>, Effie Apostolou<sup>4</sup>, Ari M. Melnick<sup>4</sup>✉ and Olivier Elemento<sup>1</sup>✉

**During the germinal center (GC) reaction, B cells undergo profound transcriptional, epigenetic and genomic architectural changes. How such changes are established remains unknown. Mapping chromatin accessibility during the humoral immune response, we show that OCT2 was the dominant transcription factor linked to differential accessibility of GC regulatory elements. Silent chromatin regions destined to become GC-specific super-enhancers (SEs) contained pre-positioned OCT2-binding sites in naive B cells (NBs). These preloaded SE 'seeds' featured spatial clustering of regulatory elements enriched in OCT2 DNA-binding motifs that became heavily loaded with OCT2 and its GC-specific coactivator OCAB in GC B cells (GCBs). SEs with high abundance of pre-positioned OCT2 binding preferentially formed long-range chromatin contacts in GCs, to support expression of GC-specifying factors. Gain in accessibility and architectural interactivity of these regions were dependent on recruitment of OCAB. Pre-positioning key regulators at SEs may represent a broadly used strategy for facilitating rapid cell fate transitions.**

The GC reaction is a transient and dynamic microanatomic structure wherein B cells undergo rapid phenotypic changes to enable immunoglobulin affinity maturation. Upon T cell-dependent activation, a subset of B cells migrate to the interior of follicles to form GCs. In the GC dark zone, B cells referred to as centroblasts exhibit extremely high rates of proliferation and mutate the variable regions of immunoglobulin genes through somatic hypermutation<sup>1</sup>. Subsequently, centroblasts migrate to the GC light zone, where they compete for affinity dependent selection by T cells. GCBs undergoing selection in the light zone are referred to as centrocytes, and those with sufficiently high-affinity B cell antigen receptors bind antigen and interact strongly with cognate follicular helper T cells. T cell help can trigger re-entry to the dark zone for additional rounds of somatic hypermutation, or terminal differentiation into antibody-secreting plasma cells<sup>1</sup>.

Emergence of the unique GC phenotype is linked to profound epigenetic reprogramming<sup>2</sup>. For example, many enhancers are toggled from an active to a poised state through recruitment of HDAC3 and LSD1 by the BCL6 transcriptional repressor during transition from NBs to centroblasts<sup>3,4</sup>. Moreover, GCBs manifest profound changes in three-dimensional chromatin architecture during NB to GCB transition, including the formation of GC-specific enhancer networks<sup>5</sup>.

Reorganization of the GC epigenome coincides with extensive transcriptional reprogramming, leading to upregulation or repression of several thousand genes<sup>6</sup>. These GC-specific events are likely initiated by several transcription factors (TFs)<sup>7</sup>. However, the mechanisms and the sequence of events through which specific TFs engage chromatin to enable the GC program remains unclear<sup>7,8</sup>.

Indeed, several hundred individual TFs are upregulated or down-regulated in GCBs. Although the repressive effect of several transcriptional regulators of the GC phenotype such as BCL6, EZH2 and FOXO1 is now established in the dark zone program in particular<sup>2</sup>, less is known about the transcriptional activators that initiate GC reprogramming. Here, we leverage chromatin accessibility, transcriptome and chromatin interaction profiling, coupled with computational analysis and functional experiments to explore how chromatin programming is organized during the humoral immune response.

## Results

**Differential accessibility defines B cells transiting the GC.** To define the chromatin accessibility regulatory landscape of B cells transiting the GC reaction in humans we performed assay for transposase-accessible chromatin sequencing (ATAC-seq) and RNA sequencing (RNA-seq) in sorted GC centroblasts, GC centrocytes, NBs, memory B cells and plasma cells (Fig. 1a, Extended Data Figs. 1a and 2a–d). We then constructed a chromatin accessibility atlas, consisting of 76,237 distinct ATAC-seq DNA elements reproducible between cell-type biological replicates. Among these, distal DNA elements located more than 2.0 kb 5' or 3' from the nearest gene transcription start site (TSS) exhibited a greater dynamic range of variability compared with promoter elements (Extended Data Fig. 2e). Accordingly, hierarchical clustering (Fig. 1b) and principal components analysis (PCA) (Extended Data Fig. 2f) of distal element accessibility clustered B cells according to developmental stage, with greater accuracy than promoter accessibility (adjusted Rand index (ARI), 0.94 distal versus 0.64 promoter,  $P < 2.2 \times 10^{-16}$ ).

<sup>1</sup>Caryl and Israel Englander Institute for Precision Medicine, Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.

<sup>2</sup>Computational Biology and Medicine Tri-Institutional PhD Program, Weill Cornell Medicine, New York, NY, USA. <sup>3</sup>The Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, NY, USA. <sup>4</sup>Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA. ✉e-mail: [amm2014@med.cornell.edu](mailto:amm2014@med.cornell.edu); [ole2001@med.cornell.edu](mailto:ole2001@med.cornell.edu)



**GC B cell de novo accessibility is linked to binding of OCT2.** Considering that gain of accessibility at TF DNA motifs generally reflects nucleosome displacement associated with TF binding, we developed a computational method to quantify TF accessibility remodeling and infer the relative contribution of 221 B cell TFs to the gain and loss in gene-distal accessibility occurring in GCBs (Fig. 2a,b). The most significant increase in accessibility between NB and GCB occurred at OCT2 recognition sequences (Fig. 2b; FDR < 0.01).

OCT2 was also the TF motif most significantly associated with gain in the activating mark H3K27ac<sup>9,10</sup> in GCBs versus NBs, with a concomitant reduction in repressive mark H3K27me3<sup>4</sup>, and transcriptional activation of nearby genes (Fig. 2c–e). OCT2 was the only TF for which all four of these parameters were highly significantly coordinated. However, the chromatin accessibility score also identified (albeit to lesser extent) TFs involved in GC formation such as ZEB1 and ID3<sup>11,12</sup>. TF binding sequences that significantly lost accessibility included BCL6, IRF4 and ETS–IRF composite elements (EICE)<sup>13</sup>. IRF4 itself, as well as genes at EICE sites, were repressed during the GC reaction, whereas BCL6 mediates transcriptional repression in GCBs<sup>13,14</sup>.

OCT2 is known to contribute to GC formation<sup>15</sup>, however our analyses suggest a broader role than previously described. To assess OCT2 binding genome-wide, we performed chromatin immunoprecipitation sequencing (ChIP-seq) for OCT2 in GCBs and identified 21,895 OCT2 binding peaks (FDR <  $1 \times 10^{-5}$ ), which were enriched for a single high-significance motif matching the reference ATGCAAT OCT2 motif (Extended Data Fig. 3a). Most OCT2-bound DAEs (91.2%) gained (rather than lost) accessibility in GCBs, whereas a majority of DAEs not bound by OCT2 (70%) showed reduced accessibility in GCBs (Extended Data Fig. 3b). Histones immediately adjacent to these OCT2-bound GCB newly accessible sites featured de novo H3K4me1 (ref. <sup>9</sup>) and H3K27ac, and the abundance of both marks was significantly higher for newly accessible sites bound by OCT2, compared with newly accessible sites without OCT2 binding (Fig. 2f,g). Differential chromatin accessibility, differential H3K27ac abundance and OCT2 binding increased with the number of OCT2 recognition sequences contained within gene-distal sites (Fig. 2h–j and Extended Data Fig. 3c). Similar findings were observed in ATAC-seq profiles of primary murine NB and GCB cells<sup>16</sup> (Extended Data Fig. 3d–i). These observations suggest that OCT2 binding may be linked to GC-specific enhancer establishment. As described previously<sup>17</sup>, we observed no detectable protein expression difference of OCT2 in GCBs relative to NBs, but a 17-fold increase in the OCT2 cofactor OCAB in GCBs versus NBs (Extended Data Fig. 3j). Thus, the effect of OCT2 on chromatin may be through its association with OCAB in GCBs.

**Gain of accessibility is pre-programmed by OCT2 in NBs.** Because OCT2 expression was relatively similar in NBs and GCBs, we wondered whether the change in chromatin accessibility in GCBs was due to redistribution of OCT2 binding throughout the genome compared with NBs. We therefore performed ChIP-seq for OCT2 in NBs. De novo motif discovery of the resulting peaks recovered a single high-significance motif, which matched the reference OCT2 motif ( $P < 10^{-16}$ ; Extended Data Fig. 4a). Comparing NBs versus GCBs, OCT2 was present at 5,089 peaks harboring an OCT2 DNA motif (direct sites) in NBs and 10,055 direct sites in GCBs (Fig. 3a). Notably, 83% of OCT2 direct targets in NBs were also bound by OCT2 in GCBs. We refer to these as ‘OCT2 pre-positioned’ sites (Fig. 3a). GCBs acquired an additional 5,819 direct sites that were not bound by OCT2 in NBs, referred to here as ‘GCB de novo’ OCT2 sites. In both cell types, the vast majority (93%) of OCT2 direct sites were localized to gene-distal regions (Extended Data Fig. 4b). Examples of pre-positioned and GCB de novo OCT2 binding sites are shown for the *DNMT1*, *SIPR2* and *MYBL1* genes (Fig. 3b and Extended Data Fig. 4c), which are induced in GCB and contribute to GC formation<sup>18–20</sup>.


We observed that GCB de novo OCT2 sites were located significantly closer to pre-positioned OCT2 sites than other accessible sites (Extended Data Fig. 4d). Reciprocally, newly accessible sites in GCBs exhibited more spatial clustering compared with sites that maintained accessibility across NBs and GCBs, or that were newly decommitted in GCBs ( $P < 2 \times 10^{-22}$ ; Extended Data Fig. 4e). Accordingly, the likelihood of observing a GCB de novo OCT2 site increased with the fraction of DNA elements in a cluster containing a pre-positioned OCT2 site ( $P = 1.2 \times 10^{-9}$ ). Thus, GCBs acquire de novo OCT2-binding sites that are clustered around pre-positioned OCT2 sites.


To assess potential mechanisms that might explain pre-positioning of OCT2 in NBs we quantified all OCT2 direct binding site motif scores, as an indicator of OCT2 binding affinity<sup>21</sup>. We found that OCT2 pre-positioned sites contained higher affinity OCT2 DNA recognition sequences compared with GCB de novo OCT2 sites ( $P < 2.2 \times 10^{-12}$ ; Fig. 3c). In both NBs and GCBs, OCT2 ChIP-seq enrichment was greater at OCT2 pre-positioned sites compared with GCB de novo or indirect sites ( $P < 1 \times 10^{-6}$ ; Fig. 3d). Indeed, ATAC-seq TF footprinting<sup>22</sup> revealed protection of OCT2 pre-positioned sites in both NBs and GCBs (although with greater protection in GCBs, Fig. 3e), whereas by contrast, GCB de novo sites were only highly protected in GCBs (protection score  $P < 2 \times 10^{-16}$ ; Fig. 3e and Extended Data Fig. 4f). This difference was further reflected by examination of nucleosome positioning. Specifically, OCT2 pre-positioned sites were nucleosome depleted and flanked by well-positioned nucleosomes in both NB and GCBs

**Fig. 2 | De novo chromatin accessibility in GC B cells is most strongly linked to DNA elements bound by OCT2.** **a**, Strategy to quantify TF accessibility remodeling in GCBs relative to NBs. The top significant TFs identified from individual regressions of accessibility changes on TF DNA motifs are included in a Bayesian multiple linear regression using horseshoe regularization. Posterior means for the coefficients of each TF motif define the TF accessibility remodeling score. **b**, Bar plot of GCB versus NB accessibility remodeling scores for expressed TFs using gene-distal DNA elements ( $n = 66,677$ ). Motif logos (left) represent position weight matrices used to map motifs in accessible sites. **c**, TF motif multiple regression effect estimates for histone H3K27ac  $\log_2$ (fold change) in biological replicate GCBs ( $n = 4$ ) relative to NBs ( $n = 4$ ) across gene-distal DNA elements ( $n = 66,677$ ). **d**, TF motif Bayesian multiple regression effect size estimates for repressive H3K27me3  $\log_2$ (fold change) in biological replicate GCBs ( $n = 3$ ) relative to NBs ( $n = 3$ ) across gene-distal DNA elements ( $n = 66,677$ ). **e**, TF motif multiple regression effect size estimates for nearest TSS gene expression  $\log_2$ (fold change) in biological replicate GCBs ( $n = 6$ ) relative to NBs ( $n = 6$ ). **f**, ATAC-seq insertion and ChIP-seq enrichment (signal/input) heatmaps centered on DAEs in GCB versus NB. OCT2-bound DAEs contain an OCT2 ChIP-seq peak in GCBs. **g**, Density plots centered on GCB de novo accessible sites comparing OCT2 binding in GCBs and H3K4me1 abundance, H3K27ac abundance and ATAC-seq insertions in NBs and GCBs. **h**, Box plot of GCB versus NB accessibility and H3K27ac. **i**,  $\log_2$ (fold change) for elements containing zero ( $n = 57,627$ ), one ( $n = 7,799$ ), two ( $n = 1,110$ ) or three or more ( $n = 141$ ) OCT2 motifs. Pair-wise comparison adjusted  $P$  values computed by Tukey’s test and  $P$  values (top) computed by type II analysis of variance (ANOVA). **j**, Bayesian regression posterior estimates for accessibility  $\log_2$ (fold change) (color scale) and GCB OCT2 ChIP-seq enrichment at DNA elements with indicated number of OCT2 recognition sequences.  $P$  values are computed by type II ANOVA. Box plot center lines represent medians, box limits indicate upper/lower quartiles, whiskers are minimum/maximum values within the 1.5 $\times$  interquartile range of the first and third quartile, and notches approximate 95% confidence intervals (CI) of the median.

(although nucleosomes shifted even further from the OCT2 motif in GCBs; Fig. 3f). In marked contrast, GCB de novo OCT2 sites were occupied by nucleosomes in NBs and subsequently evicted in GCBs (Fig. 3f). Thus, high-affinity OCT2 DNA sequences may help pre-position OCT2 in NBs for later functional relevance in GCBs, where they facilitate engagement of surrounding low-affinity OCT2 sites to establish GCB-specific enhancer activation patterning. Consistent with this notion, OCT2 pre-positioned sites manifested the greatest degree of gain of H3K4me1 and H3K27ac as well as loss of H3K27me3, compared with GCB de novo OCT2 sites (Fig. 3g and Extended Data Fig. 4g,h).

**OCAB enables de novo OCT2 binding near pre-positioned sites.** One potential explanation for the chromatin profiles of pre-positioned versus de novo OCT2 sites could be through OCT2 recruitment of the OCAB coactivator<sup>15,23,24</sup>. Notably, OCAB was shown to alleviate DNA sequence requirements of OCT2, facilitating its binding to less-optimal sites<sup>25</sup>. Along these lines, we observed significant motif divergence in GCB de novo OCT2-binding sites at positions 2, 3, 4 and 8 of the octamer element, consistent with alternate motif sequences near OCT2 pre-positioned sites that OCT2 binds in the presence of OCAB and that restrict OCT2 binding in the absence of OCAB<sup>25</sup> (Extended Data Fig. 5a).





**Fig. 3 | Gain of chromatin accessibility is preprogrammed by OCT2 in NB cells.** **a**, Venn diagram of OCT2 ChIP-seq peak overlap in NBs and GCBs. Direct sites contain an OCT2 DNA motif. OCT2 pre-positioned sites refer to direct sites bound by OCT2 in NBs and GCBs. **b**, Genome browser tracks for OCT2 and OCAB ChIP-seq enrichment, normalized ATAC-seq insertions and OCT2 direct sites in NBs and GCBs. The y axis scale is identical across all ATAC-seq samples and all ChIP-seq samples. **c**, Box plot comparing maximum OCT2 motif score in pre-positioned ( $n=4,236$ ) and GCB de novo ( $n=5,819$ ) OCT2 binding sites.  $P$  value is computed by Mann-Whitney  $U$ -test. **d**, Box plot comparing OCT2 ChIP-seq enrichment/input in NBs and GCBs across OCT2 indirect ( $n=3,732$ ), pre-positioned ( $n=4,236$ ) and GCB de novo ( $n=5,819$ ) sites.  $**P < 2 \times 10^{-16}$  by Mann-Whitney  $U$ -test. **e**, Bar plots comparing ATAC-seq chromatin protection scores computed using HINT<sup>22</sup> for GCB de novo and pre-positioned OCT2 sites in NBs and GCBs.  $P$  values are computed by Mann-Whitney  $U$ -test. \*Sites with significant observed versus expected protection at 1% FDR. **f**, Density plots of NB and GCB nucleosome dyad positions relative to OCT2 DNA motif in pre-positioned and GCB de novo OCT2 sites in NBs and GCBs. Nucleosome position and occupancy are computed from ATAC-seq data using NucleoATAC<sup>42</sup>. **g**, Read density plots of ChIP-seq enrichment/input for OCT2, H3K27ac, H3K4me1 and H3K27me3 in GCBs and NBs at pre-positioned and GCB de novo OCT2 sites. Box plots center lines represent medians, box limits indicate upper/lower quartiles, whiskers are minimum/maximum values within the 1.5x interquartile range of the first and third quartile, and notches approximate 95% CI of the median.

To further investigate the potential contribution of OCAB to chromatin effects associated with OCT2 binding, we performed ChIP-seq for OCAB in purified human GCBs and identified 14,431 OCAB peaks ( $FDR < 1 \times 10^{-5}$ ). De novo motif discovery recovered the consensus OCT2 DNA motif (Extended Data Fig. 5b), and 85.7% of OCAB peaks overlapped an OCT2 ChIP-seq peak in GCB. OCAB was found at a greater proportion of OCT2 direct sites (80.0%) compared with OCT2 indirect sites (56.1%) or sites not bound by OCT2 in GCBs (8.8%,  $P < 2 \times 10^{-16}$ ; Fig. 4a). Furthermore, OCT2 and OCAB ChIP-seq enrichments were strongly correlated across OCT2 direct sites in GCBs ( $r=0.87$ ,  $P < 2 \times 10^{-16}$ ; Fig. 4b). Like OCT2, OCAB enrichment was greater at OCT2 pre-positioned and GCB de novo OCT2 sites compared with OCT2 indirect sites ( $P < 2 \times 10^{-16}$ ), with OCT2 pre-positioned sites also showing stronger enrichment compared with GCB de novo OCT2 sites

( $P < 2 \times 10^{-16}$ ; Fig. 4c). Similar distributions of OCT2 and OCAB recruitment were observed by using ChIP-seq for OCAB in murine GCBs and OCT2 in murine splenic B cells<sup>26</sup> (Extended Data Fig. 5c,d). Hence the effect of OCT2 binding, even if present in NBs, is mainly functionally relevant in GCBs, likely through the actions of OCAB and particularly focused on licensing and activating putative gene enhancers.

**GC-specific accessibility and gene expression require OCAB.** To determine whether OCAB is required for GC-specific transcriptional reprogramming and chromatin accessibility around OCT2 pre-positioned sites we used CRISPR interference (CRISPRi) to knockdown OCAB in two GCB-derived cell lines (Extended Data Fig. 6a). PCA using chromatin accessibility and gene expression clustered both cell lines with primary GCBs (Extended Data

Fig. 6b,c), supporting their use as GCB surrogates. OCAB knock-down (referred to as OCABi) led to reduced cell growth compared with nontargeting control single guide RNAs (sgRNAs), as previously observed (Extended Data Fig. 6d,e)<sup>15</sup>. OCAB messenger RNA abundance was significantly reduced in both cell lines (Extended Data Fig. 6f,g). Unsupervised hierarchical clustering of OCABi chromatin accessibility and gene expression profiles revealed robust differences induced by depletion of OCAB (Extended Data Fig. 6h,i).

Comparing OCABi versus control, we found 939 and 838 genes significantly up- and downregulated, respectively (FDR < 0.01, absolute fold change > 2; Fig. 4d). OCAB knockdown led to a broad decrease in expression of genes normally upregulated during the NB>GCB transition (FDR < 0.001; Fig. 4d,e), including GC-specific TFs. Genes expressed at higher levels in centroblasts relative to plasma cells, memory B cells or centrocytes, as well as cell-cycle and proliferation genes were also significantly reduced by OCAB knockdown (FDR < 0.001; Fig. 4e). Key GC regulatory factors such as MEF2B and BCL6 (ref. <sup>27</sup>), as well as HOXC4, IRF8, AICDA and MYBL1 (refs. <sup>20,28–30</sup>) were downregulated. We also observed de-repression of genes usually downregulated in GCBs (Fig. 4d,e), a likely secondary effect of decreased BCL6 expression. Indeed, BCL6 target genes were significantly derepressed in OCABi versus control cells (Fig. 4e)<sup>4,31</sup>, for example, CDKN1A and S1PR1 (Fig. 4d)<sup>4,27</sup>.

From the chromatin perspective, OCAB depletion led to increased accessibility for 940 and decreased accessibility for 1113 DNA elements (FDR < 0.01). The most significant loss in accessibility upon OCAB depletion occurred at OCT2 recognition sequences (Fig. 4f) even though expression of OCT2 itself remained unchanged. Pre-positioned OCT2 sites and GCB de novo OCT2 sites exhibited significant loss of accessibility ( $P < 10^{-7}$ ), with no loss in accessibility at OCT2 indirect sites (Fig. 4g). Notably, there was a significantly greater decrease in accessibility at GCB de novo OCT2 sites compared with pre-positioned OCT2 sites ( $P = 0.002$ ), suggesting that lower-affinity OCT2-binding sites may be most dependent on OCAB for chromatin remodeling (Fig. 4g). Confirming this finding, OCT2 ChIP-seq in OCI-Ly7 cells captured 81% of OCT2 direct sites identified in NB and GCB ( $n = 10,055$  sites), only 32% of which were retained after OCAB-knockdown. Notably, OCT2 binding in OCAB-depleted cells was preferentially retained at pre-positioned sites versus GCB de novo sites (Fig. 4h). Moreover, GCB de novo OCT2 sites were 3.43 times more likely than OCT2 pre-positioned sites to show a loss of OCT2 binding in OCAB-depleted cells (99% CI = 3.02–3.91,  $P < 2.2 \times 10^{-16}$ ). Thus, OCT2 de novo binding is reliant on OCAB, consistent with the known role of OCAB in stabilizing OCT2 binding to DNA and enabling binding to motifs with imperfect octamer sequences<sup>25</sup>.

To further test the hypothesis that OCAB is a critical mediator of GC-specific chromatin accessibility patterning, we performed PCA based on the 13,658 DAEs that defined B cell subpopulations (Fig. 4i). Principal component 1 (PC1) delineated the trajectory from NB to GCB chromatin states, whereas PC2 reflected the transition to the plasma cell lineage. Projecting the accessibility profiles of OCABi and control onto the PCs defined in primary B cells yielded a partial reversal of the GCB-like chromatin state towards a NB-like chromatin state (Fig. 4j and Extended Data Fig. 6j–l). Similar results were obtained by PCA of RNA-seq data using the 3,838 differentially expressed genes among B cell subsets (Fig. 4k), where OCAB CRISPRi induced shifting towards a NB-like transcriptional program (Fig. 4l and Extended Data Fig. 6m,n). Collectively, these data suggest that OCAB plays a key role in helping OCT2 drive specific chromatin accessibility patterning and gene expression programs that define the GC phenotype.

**OCAB is sufficient for formation of GCB chromatin architecture.** Given that GCB-derived cells require OCAB to maintain GC-specific chromatin accessibility and gene expression, and that OCAB is strongly induced in GCBs<sup>26</sup> and recruited to OCT2 direct sites, we hypothesized that expression of *Ocab* in B cells might initiate chromatin and transcriptional changes that accompany the GC transition. To test this hypothesis, we ectopically expressed of *Pou2af1* in mouse splenic B cells (Extended Data Fig. 7a,b) and performed chromatin accessibility and gene expression analyses (five mice per group). We identified 784 and 741 sites with increased and decreased accessibility, respectively, relative to control (FDR < 0.1; Fig. 5a). Chromatin accessibility in ectopically expressed *Pou2af1* cells (referred to as mOCAB) was most significantly associated with *Oct2–Ocab* sites (as defined by mouse GCB *Ocab* ChIP-seq<sup>26</sup> peaks that contain an *Oct2* motif), and putative *Oct2* sites (ATAC-seq peaks containing an *Oct2* DNA motif, FDR < 0.001; Fig. 5b).


Notably, sites with increasing chromatin accessibility in mOCAB relative to control were enriched for *Oct2–Ocab* sites (NES = 2.49, FDR <  $2 \times 10^{-16}$ , Fig. 5c). Using ATAC-seq of murine NBs and GCBs<sup>16</sup>, we found that GCB newly accessible sites also became highly accessible in mOCAB versus control (NES = 2.37, FDR <  $2 \times 10^{-16}$ , Fig. 5d). Reciprocally, we observed depletion of sites that lose accessibility in GCB cells (normalized enrichment score (NES) = 1.07, FDR =  $6.7 \times 10^{-8}$ ; Fig. 5e). In addition, accessibility remodeling scores increased for *Id3*, *Zeb1* and *Tcf3* (FDR < 0.001; Fig. 5b), which also increased during the transition from NB to GCB in mouse (Extended Data Fig. 3f) and human (Fig. 2b). Reciprocally, forced expression of OCAB led to decreased accessibility at sites containing *Spi1*, *Bcl11a* and *Rela* DNA motifs (FDR < 0.001; Fig. 5b),


**Fig. 4 | OCAB recruitment by OCT2 is required to induce GC-specific chromatin accessibility and gene expression.** **a**, Bar plot showing the fraction of sites containing an OCAB ChIP-seq peak. *P* values calculated by chi-square test with Bonferroni correction. **b**, Scatter plot OCT2 and OCAB ChIP-seq enrichment/input across OCT2 direct sites in GCBs. **c**, Box plot comparing OCAB enrichment/input in GCBs across OCT2 indirect ( $n = 3,732$ ), pre-positioned ( $n = 4,236$ ) and GCB de novo ( $n = 5,819$ ) sites. Box plots center lines represent medians, box limits indicate upper/lower quartiles and whiskers are minimum/maximum values within the 1.5x interquartile range of the first and third quartile. *P* values computed by Mann-Whitney *U*-test. **d**, Volcano plot of differentially expressed genes in OCABi versus control OCI-Ly7 (OCABi  $n = 4$ , control  $n = 3$ ) and SUDHL4 (OCABi  $n = 2$ , control  $n = 2$ ). Red points indicate genes differentially expressed at FDR < 0.01 and absolute  $\log_2$ (fold change) > 1. **e**, Gene set enrichment analysis (GSEA)<sup>43</sup> dot plot showing gene sets with depletion/enrichment in OCABi versus control OCI-Ly7 and SUDHL4 cells. Color scale indicates NES and dot diameter encodes FDR *q*-value. **f**, TF accessibility remodeling scores for OCABi versus control OCI-Ly7 (OCABi  $n = 4$ , control  $n = 3$ ) and SUDHL4 (OCABi  $n = 2$ , control  $n = 2$ ). The top 21 significant (FDR < 0.001) TF motifs are shown. **g**, Bar plot showing OCABi versus control TF accessibility remodeling for NB pre-positioned ( $n = 3,636$ ), GCB de novo OCT2 ( $n = 3,510$ ) or OCT2 indirect ( $n = 3,732$ ) sites. \**P* values by Tukey's HSD; \*\**P* values by F-test compared with sites with no OCT2 binding ( $n = 65,359$ ). Error bars show 95% CIs. **h**, Bar plot showing fraction of sites with OCT2 binding by ChIP-seq in OCABi ( $n = 2$ ) versus control ( $n = 2$ ) OCI-Ly7 cells. *P* value computed by Fisher's exact test. **i**, PCA of B cell chromatin accessibility using 13,658 DAEs between B cell subtypes. **j**, Bar plot showing mean difference in chromatin PC1 loading between OCABi versus control cells. *P* values computed by two-sample *t*-test. Error bars show 95% CIs. **k**, PCA of B cell gene expression using 3,838 differentially expressed genes between B cell subtypes. **l**, Bar plot of mean difference in mRNA PC1 loading between OCABi versus control cells. *P* values computed by two-sample *t*-test. Error bars show 95% CIs.

all of which decreased significantly in mouse and human GCBs (Extended Data Fig. 3f and Fig. 2b). However, among all these TF motifs, only those for *Oct2* were significantly associated with greater mOCAB ChIP-seq enrichment ( $P < 2.2 \times 10^{-16}$ ; Fig. 5f), suggesting that chromatin accessibility changes at other TF motifs were more likely indirect effects of OCAB. Finally, mOCAB expression led to upregulation of canonical GC TFs required for the GCB phenotype, such as *Mef2b*, *Eaf2* and *Bcl6*, and downregulation of

the *Bcl6* target gene *Cdkn1a* (Fig. 5g). Altogether, these findings demonstrate that OCAB is both necessary and sufficient to initiate formation of the GCB chromatin landscape.

**OCT2–OCAB enhancers contact promoters of GC-upregulated genes.** GC-specific enhancers exhibit significant gain in looping in GCBs<sup>5</sup>. We wondered whether OCT2–OCAB complexes may play a role in enabling enhancer–promoter (EP) interactions





**Fig. 5 | OCAB expression is sufficient to drive GC-specific chromatin accessibility and gene expression in murine splenic B cells.** **a**, Heatmap of chromatin accessibility in control and mOCAB-expressing mouse splenic B cells for 784 and 741 sites with increased and decreased accessibility, respectively, in mOCAB relative to control. Splenic B cells from five mice were stimulated with LPS ex vivo and transduced with a GFP vector containing *Pou2f1* (mOCAB) or GFP only (control). **b**, TF accessibility remodeling in mOCAB ( $n = 5$ ) relative to control ( $n = 5$ ) murine splenic B cells for DNA mapped across 64,726 accessible sites. TF motifs with  $FDR < 0.001$  are shown. Error bars represent 95% CI of the mean. **c**, Results of peak-set enrichment analysis testing enrichment of OCT2-OCAB, GCB newly accessible (**d**), or GCB closing (**e**) peak-sets across 64,726 DNA elements in mouse B cells ranked by accessibility  $\log_2$  (fold change) in mOCAB ( $n = 5$ ) versus control ( $n = 5$ ). OCT2-OCAB sites defined as DNA elements that contain a mouse GCB OCAB ChIP-seq<sup>26</sup> peak with an OCT2 motif. Differentially accessible sites were determined using mouse NB and GCB ATAC-seq data<sup>16</sup> (Extended Data Fig. 3d). Enrichment statistics were computed by GSEA<sup>43</sup> applied to peaks (see Methods). **f**, Bar plot showing effect estimates for TF motifs on GCB OCAB ChIP-seq enrichment across DNA elements ( $n = 64,726$ ) in mouse B cells. **g**, Bar plot showing mRNA abundance relative to *Hprt* for *Bcl6*, *Cdkn1a*, *Eaf2* and *Mef2b* in mOCAB ( $n = 5$ ) and control ( $n = 5$ ) GFP+ viable mouse B cells.  $P$  values are calculated by Welch's  $t$ -test and error bars show s.e.m.

of GC genes. We performed H3K27Ac HiChIP in OCI-Ly7 cells, to identify chromatin interactions associated with this activating histone mark<sup>32</sup>. Reflecting the state of GCBs, OCT2 and OCAB were present in OCI-Ly7 cells at 88% of OCT2 pre-positioned sites, based on ChIP-seq in OCI-Ly7 cells. H3K27Ac HiChIP identified 5,939 high-confidence H3K27ac loops ( $FDR < 0.01$ ). Of these, 1,717 H3K27ac loops contained at least one OCT2 direct binding site with OCAB present (OCT2-OCAB sites) in one of their anchors (regions of DNA that interact to form loops), accounting for 29% of all H3K27ac loops, and 39% of all EP loops. HiChIP contact enrichment was significantly greater for EP loops

anchored by OCT2-OCAB sites, compared with EP loops not anchored by an OCT2-OCAB site (Fig. 6a). Moreover, 63% of loops involving OCT2-OCAB sites were EP loops, compared with 39% of loops not anchored by an OCT2-OCAB site (Extended Data Fig. 8a). Notably, a significantly higher fraction of OCT2-OCAB EP loops were anchored to promoters of GCB upregulated genes (Extended Data Fig. 8a). Thus, enhancers containing OCT2-OCAB preferentially interact with promoters of genes upregulated in GCBs.

An integrated enhancer activity score<sup>33</sup> based on H3K27ac ChIP-seq, HiChIP and ATACs revealed a stronger association

between active EP loops containing OCT2–OCAB sites to induce upregulation of genes in GCBs relative to NBs, compared with enhancers that lacked OCT2–OCAB sites (Fig. 6b). This effect was not observed for other key GCB TFs, such as PU.1 (ref. 34), FOXO1 (ref. 35) and MEF2B<sup>34</sup> (Extended Data Fig. 8b). Furthermore, we found significant enrichment for genes and TFs upregulated in GCBs versus NBs when ranking genes by OCT2–OCAB activity–contact scores (FDR < 0.01; Fig. 6c,d). An example of OCT2–OCAB EP contacts is shown at the MEF2B locus (Fig. 6e), where the most distal OCT2–OCAB enhancer was sensitive to OCAB depletion and showed gain in accessibility in GCBs versus NBs (Fig. 6e). Loss of OCAB in OCI-Ly7 cells also led to a significant reduction in enhancer looping between this distal OCT2–OCAB site and the MEF2B promoter (FDR < 0.01; Fig. 6e). Indeed, MEF2B expression was significantly decreased by OCAB depletion (FDR < 0.01; Fig. 6f). Hence, OCT2–OCAB complexes preferentially localize to GC-specific enhancers that experience robust changes in enhancer looping to promoters that drive differential expression of GC-specific genes.

**GCB long-range enhancer–promoter interactions require OCAB.** To determine whether OCAB was required for the connectivity of GC-specific enhancers we performed H3K27ac HiChIP in OCI-LY7 cells after OCAB CRISPRi. We found a significant reduction in contacts for 1,213 H3K27ac loops in OCAB knockdown versus controls (Extended Data Fig. 8c). OCT2–OCAB sites were present in 61.9% of OCAB-sensitive contacts, compared with 31% of loops that were not sensitive to OCAB depletion (Fig. 6g). Moreover OCT2–OCAB loops experienced significantly greater loss of contact enrichment than other loops ( $P = 2.8 \times 10^{-15}$ ), the magnitude of which increased with number of OCT2–OCAB sites present in loop anchors ( $P = 2.7 \times 10^{-16}$ ). Thus, enhancer loops containing OCT2–OCAB sites at their anchor points were preferentially sensitive to decrease in OCAB.

Strikingly, among EP loops, OCT2–OCAB binding sites were most significantly differentially enriched at intermediate (250–500 kb) and long-range (>500 kb) EP contacts (1.57 and 2.1 increased,  $P < 2.2 \times 10^{-16}$ ; Fig. 6h). Accordingly, among H3K27ac contacts, greater interaction distances were significantly associated with OCAB dependency ( $P < 2 \times 10^{-16}$ ; Fig. 6i). This effect was specific to EP loops anchored by OCT2–OCAB compared with enhancers that lacked an OCT2–OCAB complex ( $P < 2 \times 10^{-16}$ ; Fig. 6j). Moreover, the difference in OCAB dependency of interactions for enhancers with OCT2–OCAB compared with enhancers without OCT2–OCAB sites was associated with greater interaction

distance ( $P < 2 \times 10^{-16}$ ; Fig. 6j). Thus, OCAB is required for GC-specific enhancers to interact with promoters of GC-upregulated genes via intermediate and long-range looping.

**GC super-enhancers are seeded by OCT2 in NBs and require OCAB.** Expression of GC master regulatory factors such as BCL6 is driven by GC-specific SEs<sup>5</sup>, and as noted earlier, is associated with OCT2 pre-positioned binding sites that gain clusters of de novo OCT2–OCAB sites in GCBs. We wondered whether this mechanism might explain how specific pre-designated sites in the genome become SEs in GCBs. Along these lines, clustered GC de novo OCT2-binding sites featured significantly higher abundance of H3K27ac compared with GCB newly accessible sites that were not clustered ( $P < 2 \times 10^{-22}$ ; Fig. 7a). Indeed, clusters most significantly enriched for GC de novo accessibility ( $n = 44$  clusters,  $P < 0.001$ ) were near GCB-induced genes (FDR <  $1 \times 10^{-16}$ ), including critical TFs such as BCL6, ID2 and EBF1 ( $P < 0.01$ ; Fig. 7b)<sup>7</sup>. These clusters were significantly enriched for OCT2–OCAB sites ( $P < 2 \times 10^{-16}$ ) and OCT2–OCAB binding was significantly associated with greater spatial clustering ( $P < 2 \times 10^{-16}$ ; Extended Data Fig. 9a) and H3K27ac gain ( $P < 2 \times 10^{-16}$ ; Extended Data Fig. 9b), compared with distal sites not bound by OCT2–OCAB. One such cluster localized to the SE near the BCL6 gene (Extended Data Fig. 9c)<sup>5</sup>.

Mapping SEs in GCBs and NBs (Extended Data Fig. 9d,e) by H3K27ac ChIP-seq revealed a gain of 494 de novo SEs in GCBs, as well as a loss of 501 NB SEs (Extended Data Fig. 9d). Strikingly, we observed more than twofold enrichment in the observed versus expected fraction of OCT2 pre-positioned sites within GC SEs ( $P < 10^{-6}$ ; Fig. 7c), which by contrast were depleted outside GC SEs ( $P < 10^{-6}$ ; Fig. 7c). Thus, pre-positioned OCT2 sites may ‘seed’ latent GC-specific SEs in NBs that become active in GCBs upon induction of OCAB. Accordingly, we confirmed that GC-specific SEs are already enriched for OCT2 binding in NB cells, even though they first become accessible and marked by H3K4me1 and H3K27ac in GCBs (Fig. 7d and Extended Data Fig. 9c). Thus, pre-positioned OCT2 sites and strong OCAB enrichment are characteristic features of de novo SEs in GCBs.

Indeed, OCAB depletion led to significantly decreased accessibility of DNA elements in GC-specific SEs, especially those containing OCT2–OCAB sites (Fig. 7e). OCAB knockdown also led to increased accessibility of NB-specific SEs that are normally repressed in GCBs ( $P < 2 \times 10^{-16}$ ). There was no OCT2 or OCAB binding to these NB-cell SEs, suggesting that these were indirect effects. Importantly, GC-specific SEs formed longer-range

**Fig. 6 | OCAB is required for GC-specific enhancers to interact with promoters of GC-upregulated genes via intermediate and long-range looping.**


**a**, Box plot comparing H3K27ac HiChIP contact enrichment in OCI-Ly7 cells ( $n = 3$ ) for EP loops with/without OCT2–OCAB.  $P$  values calculated by Mann–Whitney  $U$ -test. **b**, Density plots of posterior predictive distributions of gene expression  $\log_2$ (fold change) in GCBs versus NBs by aggregate enhancer activity–contact score for enhancers with/without OCT2–OCAB. White lines indicate mean  $\log_2$ (fold change). **c,d**, GSEA using genes ranked by aggregate per-gene enhancer activity–contact score, with/without OCT2–OCAB and showing enrichment for genes/TFs upregulated in GCBs (FDR < 0.01,  $\log_2$ (fold change) > 1.5). **e**, UCSC genome browser tracks showing ATAC-seq elements with (red) and without (black) OCT2–OCAB. Arcs represent enhancer–gene pairs; line weight indicates activity–contact score. (Lower) Virtual 4C plot showing H3K27ac HiChIP contact enrichment between the MEF2B promoter (anchor) and surrounding 10 kb regions for OCABi ( $n = 2$ ) and control ( $n = 3$ ) OCI-LY7 cells. Shaded area represents 95% CIs. **f**, Bar plot showing mean MEF2B expression versus HPRT by qPCR in OCABi ( $n = 3$ ) and control ( $n = 3$ ) OCI-LY7 cells from three independent experiments.  $P$  values calculated using Student’s  $t$ -test. **g**, Bar plot showing fraction of OCT2–OCAB-anchored loops among loops with unchanged (OCAB-independent) or significantly decreased (OCAB-dependent) H3K27ac contact enrichment in OCABi ( $n = 2$ ) versus control OCI-Ly7 ( $n = 3$ ) cells.  $P$  value calculated by Fisher’s exact test. **h**, Box plots comparing HiChIP contact enrichment for loops with ( $n = 1,717$ ) or without ( $n = 4,222$ ) OCT2–OCAB anchor, by interaction distance. \* $P$  value by type III ANOVA F-test \*\* $P$  value for OCT2–OCAB/distance interaction by likelihood ratio test. **i**, Violin and box plots comparing  $\log_2$ (fold change) in H3K27ac HiChIP contact enrichment between OCABi and control OCI-Ly7 cells at increasing distances between loop anchors.  $P$  value by Spearman rank correlation test. **j**, Violin plots showing H3K27ac HiChIP  $\log_2$ (fold change) in OCABi versus control for loops with indicated distance between anchor mid-points, with/without OCT2–OCAB. \* $P$  value by ANOVA F-test \*\* $P$  value for OCT2–OCAB/distance statistical interaction by likelihood ratio test. Violin plots include minimum/maximum values. Box plots show center line as median, box limits as upper/lower quartiles, whiskers as minimum/maximum values within 1.5 $\times$  interquartile range of the first and third quartile, and notches as approximate 95% CIs.


EP loops than GC-silenced SEs or typical enhancers (Extended Data Fig. 9f). OCAB depletion led to GC-specific SEs becoming less interactive (Fig. 7f and Extended Data Fig. 9g,h), whereas interactivity of GC-silenced SEs was not significantly affected, suggesting a critical role for OCAB in nucleating formation and activation of GC-specific SEs.

Ranking GC-specific SEs by change in interactivity following OCAB depletion identified the BCL6 SE as the most affected (Extended Data Fig. 9i). Overall, genes with promoters contacting GC-specific SEs were significantly downregulated after OCAB

depletion (Fig. 7h and Extended Data Fig. 9j). The BCL6 SE was: (i) the most differentially loaded for H3K27Ac in GCBs versus NBs; (ii) the most heavily loaded for OCT2 in GCBs; and (iii) overall the most interactive regulatory region in the GCB genome, with 13 EP loops between the BCL6 promoter and its SE (Extended Data Fig. 9k-m).

The BCL6 SE is exclusively present and active in GCBs<sup>5</sup>. Yet our data suggest that the BCL6 SE is already present as a latent regulatory region in NBs, thanks to at least three OCT2 pre-positioned binding sites (Fig. 7h). The BCL6 SE then becomes functional





in GCBs due to subsequent upregulation and binding of OCAB to these OCT2 pre-positioned sites. In turn, this may facilitate further GC de novo clustered binding of OCT2 and OCAB and enable long-range interactions with the BCL6 TSS. Indeed

comparing the architecture of the BCL6 locus in GCBs versus NBs by 4C<sup>3</sup> underlined the significant gains in connectivity between BCL6 SE and promoter occurring around OCT2-OCAB binding sites (Fig. 7h), compared with accessible SE DNA elements that

**Fig. 7 | GC-specific super-enhancers are seeded by OCT2 in NBs and require OCAB to interact with promoters of GC master regulator genes.** **a**, Box plot of H3K27ac ChIP-seq enrichment/input for clustered/non-clustered GCB newly accessible sites. *P* values are calculated by Mann-Whitney *U*-test. **b**, Quantile-quantile plot of observed/expected *P* values (gamma-Poisson regression) for density of GCB newly accessible sites in 500 kb windows around gene TSS. Red indicates FDR < 0.01. **c**, Illustration of analysis and bar plot comparing observed/expected fractions of sites within/outside GCB SEs that contain a pre-positioned OCT2 site. *P* values are calculated by permutation test and error bars show 95% CIs of the mean. **d**, Heatmap of non-negative matrix factorization mixture coefficients distinguishing SE class. **e**, Bar plot showing OCABi (*n* = 4 OCI-Ly7, *n* = 2 SUDHL4) versus control (*n* = 3 OCI-Ly7, *n* = 2 SUDHL4) accessibility remodeling scores for OCT2-OCAB sites or all sites in GC-specific/GC-silenced SEs. *P* values are calculated by F-test and error bars show 95% CIs of the mean. **f**, Bar plot showing OCABi (*n* = 2) versus control (*n* = 3) HiChIP contact effect estimates for EP loops anchored by GC-specific/GC-silenced SEs, or outside SEs. *P* values are calculated by F-test and error bars show 95% CIs of the mean. **g**, Heatmap of mRNA abundance in NBs/GCBs for GC-specific SE target genes. (Right) Bar plot showing gene expression log<sub>2</sub>(fold change) in OCABi (OCI-Ly7 *n* = 4, SUDHL4 *n* = 2) versus control (OCI-Ly7 *n* = 3, SUDHL4 *n* = 2). Genes shown are GCB/NB differentially expressed genes with GSEA leading edge enrichment for OCABi/control log<sub>2</sub>(fold change). **h**, Arcs showing HiChIP loops in OCI-Ly7 cells (top), and 4C-seq contacts between the BCL6 promoter (anchor) and the BCL6 SE in NBs/GCBs (*n* = 3). Shaded area represents 95% CI of the mean. **i**, Box plot of GCB/NB (*n* = 2) differential 4C contacts between the BCL6 promoter and interaction domains<sup>44</sup> with/without an OCT2-OCAB site. *P* values are calculated by Welch's *t*-test. Box plots show center line as median, box limits as upper/lower quartiles, whiskers as minimum/maximum values within 1.5x interquartile range of the first and third quartile, and notches as approximate 95% CIs.

lack OCT2-OCAB binding (Fig. 7i). To further test the functional relevance of pre-positioned OCT2-binding sites, we performed CRISPRi targeting the OCT2-E1 pre-positioned site within the BCL6 SE (Fig. 8a), which manifests the most significant gain of three-dimensional looping to the BCL6 TSS in GCBs relative to NBs (Extended Data Fig. 10a). OCT2-E1 CRISPRi yielded significant reduction in BCL6 expression, similar to the effect of OCAB or OCT2 knockdown (Fig. 8b). OCT2-E1 CRISPRi impeded OCAB recruitment, H3K27ac abundance and interaction with the BCL6 TSS (Fig. 8c-f), similar to OCAB or OCT2 depletion (Fig. 8g). Thus, binding of an OCT2-OCAB complex to the prominent OCT2 pre-positioned site within the BCL6 SE is required for EP interaction and transcriptional upregulation of BCL6.

## Discussion


Our study defining the dynamic chromatin accessibility regulatory landscape of human B cells transiting the GC reaction indicates that OCT2 pre-programs the NB genome, enabling the later emergence of the canonical GC transcriptome and phenotype. This pre-programmed regulatory potential at OCT2 sites in NBs is rendered functional in GCBs by the formation and spatial expansion of OCT2-OCAB complexes to establish the chromatin architecture of GC-specific enhancers and SEs and their regulation of GC-specific TFs and effector molecules. OCT2-OCAB complexes drive activation of GC-specific enhancers and induce expression of a network GC master regulators, including MEF2B, BCL6 and others. Indeed, BCL6 expression was dependent on OCAB through the binding of an OCAB-OCT2 complex at OCT2 pre-positioned sites within the BCL6 SE, and loss of OCAB led to significant de-repression of genes normally repressed by BCL6 in GCBs<sup>4,31</sup>.

B cells in GCs acquire a highly distinct enhancer repertoire featuring thousands of GC de novo enhancers, but the regulatory logic and chromatin dynamics enabling these changes has remained unclear. We show that the entire GC-specific enhancer repertoire does not occur entirely de novo, but rather is programmed into mature B cells by OCT2 binding to high-affinity DNA motifs prior to the GC reaction. These NB pre-positioned OCT2 sites lack H3K4me1 and H3K27ac enhancer marks in NBs. Following B cell antigen receptor engagement and T cell costimulation, it is believed that OCAB is upregulated by IRF4 in a subset of mature NBs following a transient burst in IRF4 expression<sup>13,36</sup>. Once expressed, OCAB binds OCT2 to enhance and modulate its DNA binding. Previous *in vitro* studies have demonstrated that the POU<sub>S</sub> and POU<sub>HD</sub> DNA-binding domains enable OCT2

sampling of alternate, lower-affinity binding sites, and that binding of these alternate sites requires OCAB<sup>25</sup>. Our results fully support this model. Indeed, we observe low-affinity OCT2 sites near high-affinity pre-positioned OCT2 sites that define clusters of OCT2 binding at GC-specific SEs. Our study also revealed the role of clustered OCT2 binding in enabling the enhancer looping activity of critical GC-specific SEs, providing a final step in establishing the GC phenotype by inducing expression of GC master regulators including BCL6, MEF2B and IRF8. OCAB may facilitate recruitment of chromatin remodelers or cofactors necessary for enhancer loop formation, such as the Mediator complex<sup>37</sup>. The precise mechanism by which OCT2-OCAB enables enhancer looping requires further study.

Although known<sup>38</sup>, the precise mechanism through which OCT2/OCAB contribute to GC formation has remained unclear<sup>7</sup>. It was recently reported that OCT2 controls several pathways critical for normal B cell function<sup>15</sup>. Here, we show that OCT2-OCAB localizes most specifically to GC-specific SEs in GCBs. We found strong OCT2-OCAB enrichment at transient de novo accessible sites in GCBs that were decommissioned in plasma cells, as well as persistent de novo accessible sites that remained open in plasma cells. Resembling the function of pioneer TFs, OCT2 pre-programs epigenetic changes to enable cell state transition. However, whereas pioneer factors preferentially target full and partial binding motifs amid DNA sequences with high intrinsic nucleosome occupancy<sup>39</sup>, OCT2 preferentially binds near the mid-point between neighboring nucleosomes to high-affinity DNA motifs that apparently feature low intrinsic nucleosome occupancy<sup>40</sup>. A preference for binding DNA near the nucleosome entry-exit points was recently shown for the structurally similar TF OCT4<sup>41</sup>. Similar to the requirement of OCT2 for OCAB to mediate the GCB chromatin accessibility patterning, OCT4 requires the cofactor BRG1 to remodel chromatin and regulate the pluripotency network. Thus, cell type-specific interaction between a POU TF and a designated cofactor may represent a mechanism for establishing cell fate.

Altogether, we find that GC-specific de novo enhancer formation and transcriptional activation are pre-programmed into NBs and realized in GCBs by the cofactor OCAB. We propose a mechanism whereby lineage-restricted TFs bookmark potential cell fates that are elicited by cooperative binding of context-specific cofactors, giving rise to epigenetic reprogramming and cell type-specific enhancer looping that enable profound transcriptional changes. We propose that similar mechanisms may exist in other cell types, particularly when major shifts in transcriptional programming are required.



**Fig. 8 | Binding of an OCT2-OCAB complex to the prominent OCT2 pre-positioning site within the BCL6 super-enhancer is required for enhancer looping and transcriptional upregulation of BCL6.** **a**, Genome browser tracks showing GC newly accessible sites, all DNA elements identified in B cells, DNA element clusters, pre-positioned OCT2 sites and GCB de novo OCT2 sites (top); H3k27ac, OCT2 and OCAB ChIP-seq and ATAC-seq. Arrows at BCL6 TSS (TSS), a predominant OCT2 pre-positioned site (OCT2-E1, inset), and a silent region (desert). **b**, BCL6 expression in GFP+ viable OCI-Ly7 CRISPRi cells transduced with control sgRNAs or sgRNAs targeting TSS, OCT2-E1, desert, OCAB TSS (OCABi) or OCT2 TSS (OCT2i). Expression levels from GFP+ viable cells from at least three independent experiments were measured by qPCR. Bar plot shows fold change relative to mean of control cells and data points show independent experiments. \*Moderated *t*-test ( $p < 0.01$ ). Error bars show s.e.m. **c-e**, Box plots of OCT2 (**c**), OCAB (**d**) and H3K27ac (**e**) abundance at OCT2-E1 by quantitative chromatin immunoprecipitation (qChIP) in OCI-Ly7 CRISPRi cells ( $n = 4$  independent experiments) with sgRNAs targeting desert or OCT2-E1 ( $n = 4$  sgRNAs). Box plots show center line as median, box limits as upper/lower quartiles, whiskers as minimum/maximum values within 1.5x interquartile range of the first and third quartile, and notches as approximate 95% CIs. *P* values are calculated by Mann-Whitney *U*-test. **f,g**, Box plots showing 3C contacts between OCT2-E1 and TSS for OCI-Ly7 CRISPRi cells after transduction with sgRNAs targeting desert, OCT2-E1, ( $n = 4$  sgRNAs), nontargeting control, OCABi or OCT2i ( $n = 3$  sgRNAs). *P* values are calculated by Mann-Whitney *U*-test. **h**, Box plots showing results of a CRISPRi drop-out screen<sup>45</sup> for nontargeting control sgRNAs or sgRNAs targeting desert or OCT2-E1. sgRNAs were counted and the  $t_{12}/t_0$  moderated  $\log_2$ (fold change) was computed for each sgRNA using DESeq2. *P* values are calculated by Mann-Whitney *U*-test.

## Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41590-021-01025-w>.

Received: 30 September 2020; Accepted: 5 August 2021;

Published online: 23 September 2021

## References

- Mesin, L., Ersching, J. & Victora, G. D. Germinal center B cell dynamics. *Immunity* **45**, 471–482 (2016).
- Mlynarczyk, C., Fontán, L. & Melnick, A. Germinal center-derived lymphomas: the darkest side of humoral immunity. *Immunol. Rev.* **288**, 214–239 (2019).
- Hatzi, K. et al. Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. *Nat. Immunol.* **20**, 86–96 (2019).
- Hatzi, K. et al. A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. *Cell Rep.* **4**, 578–588 (2013).
- Bunting, K. L. et al. Multi-tiered reorganization of the genome during B cell affinity maturation anchored by a germinal center-specific locus control region. *Immunity* **45**, 497–512 (2016).
- Agirre, X. et al. Long non-coding RNAs discriminate the stages and gene regulatory states of human humoral immune response. *Nat. Commun.* **10**, 821 (2019).
- Song, S. & Matthias, P. D. The transcriptional regulation of germinal center formation. *Front Immunol.* **9**, 2026 (2018).
- Fernando, T. M. et al. BCL6 evolved to enable stress tolerance in vertebrates and is broadly required by cancer cells to adapt to stress. *Cancer Discov.* **9**, 662–679 (2019).
- Jiang, Y. et al. CREBBP inactivation promotes the development of HDAC3-dependent lymphomas. *Cancer Discov.* **7**, 38–53 (2017).
- Zhang, J. et al. The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma. *Cancer Discov.* **7**, 322–337 (2017).
- Arnold, C. N. et al. A forward genetic screen reveals roles for Nfkbid, Zeb1, and Ruvbl2 in humoral immunity. *Proc. Natl Acad. Sci. USA* **109**, 12286–12293 (2012).
- Chen, S. et al. Id3 orchestrates germinal center B cell development. *Mol. Cell Biol.* **36**, 2543–2552 (2016).
- Ochiai, K. et al. Transcriptional regulation of germinal center B and plasma cell fates by dynamical control of IRF4. *Immunity* **38**, 918–929 (2013).
- Ci, W. et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. *Blood* **113**, 5536–5548 (2009).
- Hodson, D. J. et al. Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2. *Proc. Natl Acad. Sci. USA* **113**, E2039–E2046 (2016).
- Yusufova, N. et al. Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. *Nature* **589**, 299–305 (2021).
- Sáez, A.-I. et al. Analysis of octamer-binding transcription factors Oct2 and Oct1 and their coactivator BOB.1/OBF1 in lymphomas. *Mod. Pathol.* **15**, 211–220 (2002).
- Shaknovich, R. et al. DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. *Blood* **118**, 3559–3569 (2011).
- Green, J. A. et al. The sphingosine 1-phosphate receptor S1P2 maintains the homeostasis of germinal center B cells and promotes niche confinement. *Nat. Immunol.* **12**, 672–680 (2011).
- Golay, J. et al. The A-Myb transcription factor is a marker of centroblasts in vivo. *J. Immunol.* **160**, 2786–2793 (1998).
- Lambert, S. A. et al. The human transcription factors. *Cell* **175**, 598–599 (2018).
- Wang, S. et al. HiNT: a computational method for detecting copy number variations and translocations from Hi-C data. *Genome Biol.* **21**, 73 (2020).
- Sauter, P. & Matthias, P. Coactivator OBF-1 makes selective contacts with both the POU-specific domain and the POU homeodomain and acts as a molecular clamp on DNA. *Mol. Cell Biol.* **18**, 7397–7409 (1998).
- Gstaiger, M., Knoepfel, L., Georgiev, O., Schaffner, W. & Hovens, C. M. A B-cell coactivator of octamer-binding transcription factors. *Nature* **373**, 360–362 (1995).
- Malik, V., Zimmer, D. & Jauch, R. Diversity among POU transcription factors in chromatin recognition and cell fate reprogramming. *Cell Mol. Life Sci.* **75**, 1587–1612 (2018).
- Song, S. et al. OBF1 and Oct factors control the germinal center transcriptional program. *Blood* **137**, 2920–2934 (2021).
- Hatzi, K. & Melnick, A. Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. *Trends Mol. Med.* **20**, 343–352 (2014).
- Park, S.-R. et al. HoxC4 binds to the promoter of the cytidine deaminase AID gene to induce AID expression, class-switch DNA recombination and somatic hypermutation. *Nat. Immunol.* **10**, 540–550 (2009).
- Cattoretti, G. et al. Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance. *J. Immunol.* **177**, 6930–6939 (2006).
- Dominguez, P. M. et al. DNA methylation dynamics of germinal center B cells are mediated by AID. *Cell Rep.* **12**, 2086–2098 (2015).
- Huang, C. et al. The BCL6 RD2 domain governs commitment of activated B cells to form germinal centers. *Cell Rep.* **8**, 1497–1508 (2014).
- Mumbach, M. R. et al. HiChIP: efficient and sensitive analysis of protein-directed genome architecture. *Nat. Methods* **13**, 919–922 (2016).
- Fulco, C. P. et al. Activity-by-contact model of enhancer–promoter regulation from thousands of CRISPR perturbations. *Nat. Genet.* **51**, 1664–1669 (2019).
- Davis, C. A. et al. The Encyclopedia of DNA elements (ENCODE): data portal update. *Nucleic Acids Res.* **46**, gkx1081 (2017).
- Dominguez-Sola, D. et al. The FOXO1 transcription factor instructs the germinal center dark zone program. *Immunity* **43**, 1064–1074 (2015).
- Willis, S. N. et al. Transcription factor IRF4 regulates germinal center cell formation through a B cell-intrinsic mechanism. *J. Immunol.* **192**, 3200–3206 (2014).
- Schoenfelder, S. & Fraser, P. Long-range enhancer–promoter contacts in gene expression control. *Nat. Rev. Genet.* **20**, 437–455 (2019).
- Schubart, K. et al. B cell development and immunoglobulin gene transcription in the absence of Oct-2 and OBF-1. *Nat. Immunol.* **2**, 69–74 (2001).
- Iwafuchi-Doi, M. & Zaret, K. S. Pioneer transcription factors in cell reprogramming. *Gene Dev.* **28**, 2679–2692 (2014).
- Zhu, F. et al. The interaction landscape between transcription factors and the nucleosome. *Nature* **562**, 76–81 (2018).
- Michael, A. K. et al. Mechanisms of OCT4–SOX2 motif readout on nucleosomes. *Science* **368**, 1460–1465 (2020).
- Schep, A. N. et al. Structured nucleosome fingerprints enable high-resolution mapping of chromatin architecture within regulatory regions. *Genome Res.* **25**, 1757–1770 (2015).
- Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl Acad. Sci. USA* **102**, 15545–15550 (2005).
- Raviram, R. et al. 4C-ker: a method to reproducibly identify genome-wide interactions captured by 4C-Seq experiments. *PLoS Comput. Biol.* **12**, e1004780 (2016).
- Chu, C.-S. et al. Unique immune cell coactivators specify locus control region function and cell stage. *Mol. Cell* **80**, 845–861.e10 (2020).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2021

## Methods

**Experimental model and subject details.** *Isolation and ex vivo infection of mouse splenic B cells.* The Research Animal Resource Center of the Weill Cornell Medical College approved all mouse procedures. For all mice experiments, mice were between 2 and 4 months old and harmonic representation of male and female was used. Mice were housed in air-filtered cages, one to five mice per cage, provided with standard rodent food, given free access to food and water, on a 12:12 light/dark cycle. The temperature was kept at 22 °C (20–26 °C) and humidity at 45% (40–60%).

Mouse splenocytes from C57BL/6J (<https://www.jax.org/strain/000664>) were enriched using the EasySep Mouse B Cell Isolation Kit (Stem Cell Technologies, catalog no. 19854), and plated in RPMI 10% fetal bovine serum (FBS) + (100 U ml<sup>-1</sup> penicillin and 100 µg ml<sup>-1</sup> streptomycin) + 55 mM 2-mercaptoethanol. Cells were preincubated for 6 h in the presence of 25 µg ml<sup>-1</sup> lipopolysaccharide (LPS). Cells were spininfected with retrovirus pRetroX-IRES-ZsGreen1 (empty vector as control, Takara Bio, catalog no. 632520) or with pRetroX-mOcab-IRES-ZsGreen1 that expressed the mouse *Pou2af1* gene in the presence of 8 µg ml<sup>-1</sup> polybrene (Millipore TR-1003) at 800 r.c.f. for 90 min at 24 °C. Cultures were collected and green fluorescent protein positive (GFP+) viable cells were isolated by FACS on a BD Aria II sorter 3 d after infection, and RNA extracted using TRIzol (Invitrogen, catalog no. 15596026), as per the manufacturer's instructions. Additional cells, collected 3 d after infection were further processed for ATAC-seq.

*Isolation of human B cell populations by FACS.* The Institutional Review Board at Weill Cornell Medical College approved all use of human tissue (IRB#0805009767). All individuals provided informed consent and no compensation was provided to tissue donors. Primary cells were isolated from fresh deidentified human tonsillectomy specimen tonsillar lymph nodes by density gradient centrifugation and cryopreserved in 90% FBS with 10% DMSO. Cellular populations were sorted on a BD Influx cytometer. Prior to cell sorting, lymphocytes were resuspended in 90% Iscove's modified Dulbecco's medium (Thermo Fisher Scientific, catalog no. 12330053) with 10% FBS for 1 h at 37 °C. Lymphocytes were then labeled with anti-CD20 (0.01 dilution), anti-CD10 (0.05 dilution), anti-CD44 (0.025 dilution), anti-CD27 (0.03 dilution), anti-CD38 (0.03 dilution), anti-IgD (0.03 dilution) and anti-CXCR4 (0.1 dilution) conjugated fluorochromes (Supplementary Table 1). 4,6-Diamidino-2-phenylindole was used to exclude nonviable cells. All antibodies used were commercially available and validated by the manufacturers and used according to the manufacturer's instructions. When possible, positive and negative control populations were used for validation of the antibody.

*Cell lines.* Human DLBCL cell lines were cultured in medium containing 80% Iscove's modified Dulbecco's medium (Thermo Fisher Scientific, catalog no. 12440053) with 20% FBS (OCI-Ly7) or 90% RPMI-1640 (Thermo Fisher Scientific, catalog no. 11875085) with 10% FBS (SU-DHL-4), each supplemented with 1% glutamine and 1% penicillin/streptomycin (Thermo Fisher Scientific, catalog no. 15140122). OCI-Ly7 were obtained from Ontario Cancer Institute in June 2011. SU-DHL-4 cells were obtained from ATCC (CRL-2957). HEK293T (CRL-3216, ATCC) cells were cultured in complete DMEM (Thermo Fisher Scientific, catalog no. 11995040) supplemented with 10% fetal calf serum and 1% penicillin/streptomycin (Thermo Fisher Scientific, catalog no. 15140122).

**Method details.** *ChIP and ChIP-seq library preparation.* ChIP-seq was performed as described<sup>46</sup> (Yu et al., 2015) with the following modifications. Some 2 × 10<sup>7</sup> cells were fixed in 1% formaldehyde for 10 min at room temperature, and fragmentation of fixed chromatin was obtained from isolated nuclei by sonication (Branson Sonifiers, Branson). To enrich for short chromatin fragments (200–700 bp), 5 µg of antibody was added to the chromatin lysate and incubated overnight at 4 °C. The following day, Dynabeads protein A (Thermo Fisher Scientific, catalog no. 10002D) was added and incubated with rotation at 4 °C for 1.5 h. Enriched DNA was isolated through extensive wash steps, subsequent reverse cross-linking, and purification using DNA Clean & Concentrator Kit (Zymo Research, catalog no. D4014). ChIP-seq libraries were prepared from 2–5 ng of ChIP DNA. After end-repair (End-It End-Repair Kit, Lucigen, catalog no. ER0720), A-tailing (3'→5' exo-Klenow fragment, NEB, catalog no. M0212S), and ligation (Quick Ligation Kit, NEB, catalog no. M2200S) with barcodes (NEXTflexChIP-Seq Barcodes, PerkinElmer, catalog no. #NOVA-514121), barcoded DNA was amplified by 12 cycles of PCR using Phusion High-Fidelity DNA Polymerase (NEB, catalog no. M0530S). Libraries were then sequenced on Illumina HiSeq 2500 as 50-bp single-end runs at the Genomics Resource Center at the Rockefeller University. Antibodies used were OCT2: sc-233, Santa Cruz; OCAB: sc-955, Santa Cruz.

Histone ChIPs, including H3K4me1, H3K27ac and H3K27me3 in human NBs and GCBs and human cell lines were performed as described previously<sup>9</sup>. Human GCB and NB histone ChIP-seq raw sequence data generated by the Blueprint Consortium were downloaded from the European Genome-Phenome Archive.

*ATAC-seq.* ATAC-seq profiles were collected for primary human lymphocytes and DLBCL cell lines. Populations of cells were isolated as above and ATAC-seq was performed as previously described according to the omni-ATAC-seq method. Fifty thousand cells were resuspended in 1 ml of ATAC-seq resuspension buffer

(RSB; 10 mM Tris-HCl pH 7.4, 10 mM NaCl and 3 mM MgCl<sub>2</sub> in water) and centrifuged at 500 r.c.f. (g) and 4 °C for 5 min. Supernatant was aspirated by pipetting and cells were resuspended in 50 µl of ATAC-seq RSB containing 0.1% NP-40, 0.1% Tween-20 and 0.01% digitonin, and incubated on ice for 3 min. Following lysis, 1 ml of ATAC-seq RSB containing 0.1% Tween-20 was added, and nuclei were centrifuged at 500 r.c.f. (g) and 4 °C for 10 min. Supernatant was then aspirated by pipetting and nuclei were resuspended in 50 µl of transposition mix (25 µl of 2× TD buffer, 2.5 µl of tagment DNA enzyme, 16.5 µl of PBS, 0.5 µl of 1% digitonin, 0.5 µl of 10% Tween-20 and 5 µl of water) and incubated at 37 °C for 30 min in a thermomixer with shaking at 1,000 r.p.m. Reactions were cleaned up with Zymo DNA Clean and Concentrator kit (catalog no. D5205). ATAC-seq DNA libraries were prepared as described previously, and library concentration was checked by quantitative PCR (qPCR) using the KAPA Library Quantification Kit. DNA libraries were sequenced on a HiSeq2000 (Illumina) or HiSeq4000 (Illumina) at the Weill Cornell Epigenomics Core Facility.

*RNA-seq and qPCR.* Total RNA was extracted from ≥ 5 × 10<sup>5</sup> cells using TRIzol (Life Technologies) and RNeasy isolation kit (Qiagen) according to the manufacturer's instructions. RNA concentration was determined using Qubit (Life Technologies) and integrity was verified using Agilent 2100 Bioanalyzer (Agilent Technologies). Paired-end sequencing libraries were prepared using the TruSeq Stranded mRNA sample kit (Illumina). Pair-end sequencing was performed on Illumina HiSeq2000 (paired-end 50-bp reads) or Illumina HiSeq4000 (paired-end 75bp reads).

For qPCR, total RNA was reverse transcribed with oligo-dT primers using the Verso cDNA kit (Thermo Fisher Scientific) according to the manufacturer's protocol. Real-time quantitative PCR with reverse transcription (RT-qPCR) was performed using PerfeCTa SYBR Green FastMix Reaction Mixes on a QuantStudio 6 Flex PCR System. Expression was quantified relative to mean of control samples using the  $\Delta\Delta$ Ct method after normalization to *HPRT*.

*Generation of CRISPRi cell lines.* CRISPRi OCI-Ly7 and SU-DHL-4 cell lines were generated by lentiviral transduction of pHR-SFFV-dCas9-BFP-KRAB followed by flow sorting for BFP high populations. Cells were expanded and sorted again after 1–2 weeks, and this was repeated two or three times. pHR-SFFV-dCas9-BFP-KRAB (46911, Addgene) was a gift from Stanley Qi and Jonathan Weissman.

*CRISPRi-mediated interference.* Individual guide RNA (gRNA) oligos were ordered from IDT and cloned into pLKO5.C+E.sgRNA.EFS.GFP for qPCR, ATAC-seq, RNA-seq, HiChIP and drop-out experiments. gRNA sequences are listed in Supplementary Table 2. gRNA constructs were lentivirally transduced into OCI-Ly7 or SU-DHL-4 CRISPRi cell lines. GFP+ cells were isolated by FACS on a BD Influx cytometer using BD FACSDiva v.9.0 software 2 d after transduction. For drop-out curves, cells were infected with GFP-tagged constructs at an infection rate of 20–50% and the fraction of GFP positive cells was monitored by FACS every 3–4 d using FlowJo version 9. The fraction of GFP positive cells was normalized to the fraction of GFP positive cells at day 3–4. Custom R code was used for analysis of FACS data and plotting of results.

*HiChIP.* HiChIP was performed as previously described using an H3K27ac antibody<sup>47</sup> (Fisher): 50 and 17 ng of total post-ChIP DNA was used for GC and NB samples, respectively, for library preparation. Following biotin pull-down the samples were tagged with Tn5 (Illumina) as previously described<sup>47</sup> and libraries were generated using six and eight cycles of PCR amplifications for GC and NB samples, respectively. After dual size selection with Ampure XP beads, libraries size was measured by BioAnalyzer. Libraries were sequenced on a HiSeq4000 platform on PE50 mode.

*Immunoblotting.* Lysates of DLBCL lymphoma cell lines and isolated cell populations were prepared using 25 mM Tris, pH 7.4, 150 mM NaCl, 0.5% NP-40, 0.1% SDS and complete protease inhibitor cocktail (Roche) lysis buffer. Protein lysates were resolved by SDS-PAGE, transferred to a polyvinylidene difluoride membrane and probed with primary antibodies to the following: BOB-1/OBF-1 (1:100, Cell Signaling Technology, catalog no. #33483S) and Oct2 (1:500, Thermo Fisher Scientific, catalog no. RB-9297) and GAPDH (1:10,000, Santa Cruz, catalog no. sc-25778). Membranes were then incubated with corresponding horseradish peroxidase-conjugated secondary antibodies, and signal was detected using enhanced chemiluminescence (ChemiDoc Touch, Bio-Rad Laboratories).

*Ex vivo infection of mouse B cells.* Mouse splenocytes were enriched using the EasySep Mouse B Cell Isolation Kit (Stem Cell Technologies, catalog no. 19854), and plated in RPMI 10% FBS + (100 U ml<sup>-1</sup> penicillin and 100 µg ml<sup>-1</sup> streptomycin) + 55 mM 2-mercaptoethanol. Cells were preincubated for 6 h in the presence of 25 µg ml<sup>-1</sup> LPS. Cells were spininfected with retrovirus pRetroX-IRES-ZsGreen1 (empty vector as control, Takara Bio, catalog no. 632520) or with pRetroX-mOcab-IRES-ZsGreen1 that expressed the mouse *Pou2af1* gene in the presence of 8 µg ml<sup>-1</sup> polybrene (Millipore, catalog no. TR-1003) at 800 r.c.f. for 90 min at 24 °C. Cultures were collected at different time points after infection, and RNA extracted using TRIzol (Invitrogen, catalog no. 15596026), as per the

manufacturer's instructions. Additional cells, collected 3 d after infection were further processed for ATAC-seq.

**Quantification and statistical analysis.** *ATAC-seq alignment, filtering and peak calling.* Paired-end ATAC-seq reads were trimmed to remove adapter sequences using NGmerge with the options '-z -u 41 -a<sup>48</sup>'. Trimmed read pairs were aligned to version 38 of the human reference genome (hg38) using bowtie2 with the following options: '-X2000 -local -mm -k 4'. Aligned reads were sorted and filtered to exclude reads mapping to mitochondrial DNA and black-listed regions, and duplicate read pairs were removed using the 'MarkDuplicates' program in picard tools (<http://broadinstitute.github.io/picard>). This resulted in the final aligned, sorted and filtered BAM file that was used for all subsequent analysis. The ATAC-seq processing and alignment pipeline is available at <https://github.com/DoaneAS/atacflow>.

ATAC-seq library quality was assessed from the aligned and filtered libraries by computing the fraction of reads in peaks (FRIP-score) using a set of universal DHS regions provided by ENCODE ([https://storage.googleapis.com/encode-pipeline-genome-data/hg38/ataqc/reg2map\\_honeybadger2\\_dnase\\_all\\_p10\\_ucsc.hg19\\_to\\_hg38.bed.gz](https://storage.googleapis.com/encode-pipeline-genome-data/hg38/ataqc/reg2map_honeybadger2_dnase_all_p10_ucsc.hg19_to_hg38.bed.gz)). ATAC-seq samples with FRIP-score  $\geq 0.3$  were retained for analysis. In addition to standard quality metrics, we assessed TSS enrichment, TSS chromatin accessibility and TSS nucleosome positioning (see Nucleosome mapping below) using ATAC-seq data and confirmed the expected correlations with transcript abundance (Extended Data Fig. 1b–e). ATAC-seq peaks were called from Tn-5 corrected insertions using MACS2 callpeak with option '-g hs -nomodel -shift -75 -extsize 150 -keep-dup all -call-summits'.

*ChIP-seq alignment and peak calling.* ChIP-seq libraries were aligned to GRCh38 v.24 'no-alt' or mm10 reference genomes for human and mouse samples, respectively, and filtered for quality and PCR duplicates according to Encode 3 uniform processing pipeline<sup>49</sup>, available at <https://github.com/ENCODE-DCC/chip-seq-pipeline2>. ChIP-seq library quality was measured using the non-redundant fraction (NRF) and PCR bottlenecking coefficients 1 (PBC1) and 2 (PBC2), as defined previously<sup>49</sup>. Libraries with NRF > 0.9, PBC1 > 0.9 and PBC2 > 10 were retained for analysis. MACS v.2.0 was used for ChIP-seq peak calling and for generating fold change over control signal tracks according to Encode 3 uniform processing guidelines<sup>49</sup>. Alignment and peak calling were performed for MINT-ChIP libraries<sup>50</sup> as described previously<sup>50</sup>.

*B cell chromatin accessibility peak atlas.* Reproducibility of ATAC-seq called peaks was defined using a 1% irreproducibility discovery rate as described. A B cell chromatin accessibility atlas containing 500 bp disjoint genomic intervals (DNA elements) was constructed from called peak summits that were reproducible across biological replicates using an iterative peak-ranking method as previously described<sup>51</sup>. To quantify accessibility across samples, the number of single-base Tn-5 corrected insertions that fell within each 500 bp interval was counted from ATAC-seq bam files using the command 'pyatac counts' in the nucleoATAC package<sup>42</sup>.

Differential accessibility between conditions was computed using DESeq2. Normalization factors included in the call to DESeq2 were computed by quantile normalization with GC sequence content bias correction using the R package EDASeq. The chromatin accessibility  $\log_2(\text{fold change})$  reported and used in all analyses were computed and shrunken using the 'lfcShrink' function with option 'type = ape' in the DESeq2 R package. Differentially accessible DNA elements were identified at FDR < 0.01 unless noted otherwise. For clustering of ATAC-seq data, a normalized counts matrix was computed using the *varianceStabilizingTransformation* function in DESeq2 after inclusion of the above normalization factors. Sample dendrograms were produced using Pearson correlation with average-linkage hierarchical clustering. The ARI was used to compare the grouping of samples obtained from unsupervised clustering to known sample cell types. To compare the ARI for distal and promoter sites, 1,000 sites were sampled without replacement from all distal or all promoter sites and the ARI was computed from the resulting clustering result. This procedure was repeated for 500 iterations, and the resulting ARI values for distal and clustered sites were compared by *t*-test.

All gene-based annotation was performed using Gencode Release 32 (GRCh38.p13, [https://www.encodegenes.org/human/release\\_32.html](https://www.encodegenes.org/human/release_32.html)). DNA elements were assigned to genes according to the nearest TSS of a protein coding gene with mean expression  $\geq 1$  transcripts per kilobase million (TPM) in any one cell type, unless noted otherwise. DNA elements were classified as distal elements unless they were located within 2.5 kb of a gene promoter.

To assess ChIP-seq abundance for each ATAC-seq DNA element, mean fold enrichment over input was computed over 1 kb or 500 bp regions centered on ATAC-seq peak summits, for histone ChIP-seq or TF ChIP-seq, respectively. SEs were mapped from ChIP-seq target and input bam files using ROSE with default parameters.

*Nucleosome mapping.* Nucleosome position and occupancy in genomic regions within 1 kb of accessible chromatin were determined using the nucleoATAC python package<sup>42</sup>. ATAC-seq bam files were pooled by cell type, and peaks were called using

MACS2 'callpeak' with options '-g hs -nomodel -shift -75 -extsize 150 -keep-dup all -broad-cutoff 0.1'. The resulting peaks were expanded by 500 bp in the 5' and 3' directions using bedtools and the resulting bed file was used as the input ranges in the call to nucleoATAC. The 'nucmap\_combined.bed.gz' output from nucleoATAC was used to define nucleosome positions for subsequent analysis.

*DNA motif analysis and TF footprinting.* De novo motif discovery was performed using ChIP-seq peak summits or ATAC-seq peak summits as input to HOMER findMotifsGenome.pl with the following options: '-bits -size 150 -len 8,10,12,14 -mis 3 -mask'. Divergence between similar motifs was computed using the R package motifDiverge<sup>52</sup>. Known motifs were mapped to DNA elements using the R package motifMatchR<sup>53</sup>.

To estimate patterns of accessibility associated with TF binding, and considering the potential TF protection of DNA from TN5 transposition as well as the sequence bias of TN5, pooled replicate ATAC-seq bam files were analyzed using HINT with default options for ATAC-seq data<sup>54</sup> and using the B cell peaks atlas genomic coordinates.

*Accessibility remodeling regression models.* Known TF motifs were identified in genomic DNA sequences using the R package motifMatchR v.1.8.0 (<https://bioconductor.org/packages/release/bioc/html/motifmatchr.html>) with the options 'p.cutoff = 1e-6'. A filtered and curated collection of human TF motifs was obtained from chromVARmotifs ('human\_pwmms\_v2', <https://github.com/GreenleafLab/chromVARmotifs>)<sup>53</sup>. AP-1-IRF and EICE composite motifs were obtained from Homer collection ('homer\_pwmms', <https://github.com/GreenleafLab/chromVARmotifs>) bZIP:IRF and PU.1-IRF(ETS:IRF), respectively. TFs were filtered to include those with transcript abundance > 1 TPM in at least one B cell type (see RNA-seq methods).

To calculate change in accessibility remodeling, we first performed a linear regression of the shrunken  $\log_2(\text{fold change})$  on each TF motif independently, resulting in one regression model for each of 221 expressed TFs. Hypothesis testing of estimated coefficients was performed by Wald-test with a heteroskedasticity-consistent robust covariance estimator, using the 'sandwich' package in R. TF coefficient estimate *P* values were corrected for multiple-hypothesis testing and significant TFs (FDR *q*-value <  $1 \times 10^{-5}$ ) were retained for Bayesian multiple regression.

Because the transcriptional networks that drive cellular reprogramming are most often due to a small number of cell type-specific master regulators<sup>55,56</sup>, the activity of most expressed TFs is expected to have a modest impact on cell type-specific changes in accessibility. We incorporated this information by setting a horseshoe prior on the covariates (TFs) in a Bayesian multiple regression of change in accessibility on the TFs identified by linear regression above. Bayesian multivariate regression with NUTS MCMC sampler was performed in R using the BRM package and RSTAN.

*Spatial clustering of peaks.* Peak clusters were defined using community detection on a weighted graph of site–site distances bounded at 50 kb. The edge weight *w* between peaks *i* and *j* was defined as  $w = \frac{1}{\log(D_{ij})}$ , where  $D_{ij}$  is the distance in base pairs between the center of peak, and peak<sub>*j*</sub>. Peak clusters were identified using the infoMAP community detection algorithm in the R package iGraph, and intracommunity edges were used to generate a graph of peak clusters for further analysis. Peak 'coreness' was computed using iGraph package in R. The *k*-core of graph is a maximal subgraph in which each vertex has at least degree *k*. The coreness of a vertex (peak) is *k* if it belongs to the *k*-core but not to the (*k*+1)-core.

*Projection of cell line accessibility onto principle components of cell state transitions.* PCA was performed on our B cell normalized ATAC-seq profiles across DAEs between B cell phenotypes. The accessibility profiles of control and OCABi OCI-Ly7 and SUDHL4 cells were then projected onto the principal components defined from B cells. Differences in the loading of a PC between OCABi and control were tested for significance by two-sample *t*-test.

*Generalized low rank models and non-negative matrix factorization.* We computed the quantile-normalized ATAC-seq insertion density, as well as ChIP-seq enrichment for activating histone marks H3K4me1 and H3K27ac, and binding of OCT2 and OCAB for each 500 bp DNA element. For histone marks only, the 500 bp region was expanded by 250 bp in the forward and reverse directions to capture neighboring nucleosomes. A matrix was constructed containing ATAC-seq counts normalized by variance stabilized transformation and ChIP-seq fold enrichment/input, for each gene-distal DNA element overlapping a GC or NB called SE. This matrix was quantile normalized and matrix factorization was performed using the H2O package in R and specifying a Huber loss function, and non-negative regularization.

*Identifying loci enriched for differentially accessible sites.* fishHook<sup>57</sup> (<https://github.com/mskilab/fishHook>) was used to model background chromatin accessibility and nominate differentially accessible regulatory hotspots during the transition from NB to GCB. A negative binomial generalized linear model was used to model genome-wide density of DAEs across the intersection of an eligible territory (atlas of accessible sites in B cells) and set of hypothesis intervals ( $\pm 250$  kb of the TSS

for genes expressed  $\geq 1$  TPM in at least one stage of B cell development) as a function of genomic covariates represented by the fractional overlap with all accessible sites in B cells and all reference genome TSS. The maximum likelihood fit of a fishHook model, implemented as a gamma-Poisson regression, assigns weights to covariates and an expected DAE density to each hypothesis interval. An enrichment value is computed at each hypothesis interval as the ratio of observed to expected DE density. The model is further used to define a cumulative distribution function for DE density at each interval. Each interval is then assigned a one-sided *P* value as the probability that the DE density is greater or equal to the observed density.

**RNA-seq analysis.** Paired-end sequencing reads were aligned to human reference genome GRCh38 (hg38) without alternate alleles using STAR. RSeQC (<http://rseqc.sourceforge.net>) was used to verify library quality. Samples with at least 20 million uniquely mapping reads were retained for analysis, and the percent of mRNA bases per sample ranged from 70% to 83%.

To quantify transcript abundance, a decoy-aware transcriptome was generated from Gencode Release 32 transcriptome using Salmon v.1.1.0 (ref.<sup>58</sup>). Quantification was performed using the 'salmon quant' command and options '-l A -validateMappings -numGibbsSamples 10 -gcBias'. Transcript-level quantification and bias corrections were summarized to the gene-level using the tximeta Bioconductor package, and differential expression analysis was performed using gene counts and average transcript lengths with DESeq2. For differential expression analysis of cell line CRISPRi studies, baseline differences between cell lines were accounted for by including a cell line covariate (OCI-Ly7 or SUDHL4) in the DESeq2 design.

**HiChIP analysis.** H3K27ac HiChIP sequencing reads were trimmed for adapter sequences using ngTrim. Trimmed reads were aligned to hg38 and filtered to generate a file of paired-end tags (PETs) using the HiC-Pro pipeline<sup>59</sup>. Loops were called using cLoops with default HiChIP parameters. The H3K27ac contact frequency for each loop was defined as the ratio of supporting PETs to the mean PETs of nearby permuted regions, as defined in cLoops<sup>60</sup>. To confirm H3K27ac contact enrichment for a set of loops and compare between control and OCABi OCI-Ly7 cells, we used APA with 5 kb bin size. The peak to lower-left ratio was computed using juicer apa with default parameters. Significance testing was performed by paired *t*-test with Holm–Bonferroni multiple-testing correction. Fold changes in OCABi/control were computed for pairs of loop anchors using PET raw counts as input to a generalized linear model (GLM) in the R package edgeR. Virtual 4C plots were generated from VC-SQRT corrected PETs, and library size normalization was applied across samples using quantile normalization.

To estimate the regulatory input of ATAC-seq DNA elements to a gene's expression, ATAC-seq DNA elements, GC B cell H3K27ac ChIP-seq, OCI-Ly7 H3K27ac HiChIP and GC B cell mRNA abundance were used to estimate an activity by contact model as previously described<sup>33</sup>. To estimate the regulatory contribution of OCT2–OCAB sites and non-OCT2–OCAB sites for a gene's change in expression in GCB versus NB cells, the aggregate activity–contact score for enhancers with OCT2–OCAB sites and for enhancers without OCT2–OCAB sites was calculated for each gene.

**4C-seq analysis.** Published NB and GCB 4C-seq sequencing reads<sup>5</sup> were obtained from SRA and aligned to hg38 as described<sup>14</sup>. Differential cis-contacts were computed using the 4C-ker package, and resulting normalized contacts and  $\log_2(\text{fold change})$  values were used for 4C plots.

**Statistical analysis.** All *P* values calculated from statistical tests with symmetrically distributed test statistics represent two-sided hypothesis testing. All statistical analysis was performed in R v.3.8 unless noted otherwise.

**Reporting Summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

## Data availability

All sequencing data generated for this study are available in Gene Expression Omnibus (accession number GSE159314). Source data are provided with this paper.

## Code availability

All code used for processing and primary analysis of sequencing data is available at <https://github.com/DoaneAS/atacflow> for ATAC-seq, <https://github.com/DoaneAS/rnaflow> and <https://github.com/nf-core/rnaseq> for RNA-seq, and <https://github.com/nf-core/chipseq> for ChIP-seq.

## References

46. Yu, M. et al. RNA polymerase II-associated factor 1 regulates the release and phosphorylation of paused RNA polymerase II. *Science* **350**, 1383–1386 (2015).
47. Giammartino, D. C. D. et al. KLF4 is involved in the organization and regulation of pluripotency-associated three-dimensional enhancer networks. *Nat. Cell Biol.* **21**, 1179–1190 (2019).

48. Gaspar, J. M. NGmerge: merging paired-end reads via novel empirically-derived models of sequencing errors. *BMC Bioinformatics* **19**, 536 (2018).
49. Landt, S. G. et al. ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. *Genome Res.* **22**, 1813–1831 (2012).
50. Rivas, M. A. et al. Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation. *Nat. Immunol.* **22**, 240–253 (2021).
51. Corces, M. R. et al. The chromatin accessibility landscape of primary human cancers. *Science* **362**, eaav1898 (2018).
52. Kostka, D., Friedrich, T., Holloway, A. K. & Pollard, K. S. motifDiverge: a model for assessing the statistical significance of gene regulatory motif divergence between two DNA sequences. *Stat. Interface* **8**, 463–476 (2015).
53. Schep, A. N., Wu, B., Buenrostro, J. D. & Greenleaf, W. J. chromVAR: inferring transcription-factor-associated accessibility from single-cell epigenomic data. *Nat. Methods* **14**, 975–978 (2017).
54. Li, Z. et al. Identification of transcription factor binding sites using ATAC-seq. *Genome Biol.* **20**, 45 (2019).
55. Tsankov, A. M. et al. Transcription factor binding dynamics during human ES cell differentiation. *Nature* **518**, 344–349 (2015).
56. Saint-André, V. et al. Models of human core transcriptional regulatory circuitries. *Genome Res.* **26**, 385–396 (2016).
57. Imielinski, M., Guo, G. & Meyerson, M. Insertions and deletions target lineage-defining genes in human cancers. *Cell* **168**, 460–472.e14 (2017).
58. Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. *Nat. Methods* **14**, 417–419 (2017).
59. Servant, N. et al. HiC-Pro: an optimized and flexible pipeline for Hi-C data processing. *Genome Biol.* **16**, 259 (2015).
60. Cao, Y. et al. Accurate loop calling for 3D genomic data with cLoops. *Bioinformatics* **36**, 666–675 (2019).
61. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
62. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol. Cell* **38**, 576–589 (2010).

## Acknowledgements

A.S.D. is funded by NCI (1 F31 CA220981-01). A.M.M. and O.E. are funded by Leukemia and Lymphoma Society SCOR 7012-16 and SCOR 7021-20. O.E. is supported by Janssen and Eli Lilly research grants, NIH grants UL1TR002384, R01CA194547 and LLS SCOR grant 180078-02. A.M.M. is funded by NCI R35 CA220499, and NCI P01 CA229086, LLS TRP 6572-19, The Chemotherapy Foundation and the Follicular Lymphoma Consortium. R.G.R. is supported by NIH grants R01A1148387 and R01CA178765 and Leukemia and Lymphoma Society SCOR 7021-20. This study makes use of data generated by the Blueprint Consortium. A full list of the investigators who contributed to the generation of the data is available from [www.blueprint-epigenome.eu](http://www.blueprint-epigenome.eu). Funding for the project was provided by the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement no 282510 BLUEPRINT.

## Author contributions

A.S.D., A.M.M. and O.E. conceived the study. A.S.D., A.A., D.C.D.G., E.A., A.M.M., J.C.H., C.-S.C., Y.J., M.A.R. and O.E. designed the methods. A.S.D., D.C.D.G., N.Y., J.C.H., Y.J., M.A.R. and C.-S.C. undertook the investigation. A.S.D. carried out the formal analysis. A.S.D., A.M.M. and O.E. wrote the manuscript. R.G.R., E.A., A.M.A. and O.E. supervised the study.

## Competing interests

A.M.M. receives research funding from Janssen and Daiichi Sankyo, has consulted for Constellation, Jubilant and Epizyme, and is on the advisory board of KDAC. O.E. is scientific advisor and equity holder in Freenome, Owkin, Volastra Therapeutics and OneThree Biotech. A.S.D., C.-S.C., D.C.D.G., M.A.R., J.C.H., Y.J., N.Y., A.A., R.G.R. and E.A. declare no competing interests.

## Additional information


**Extended data** is available for this paper at <https://doi.org/10.1038/s41590-021-01025-w>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41590-021-01025-w>.


**Correspondence and requests for materials** should be addressed to Ari M. Melnick or Olivier Elemento.

**Peer review information** *Nature Immunology* thanks Marcus Clark, Rhys Allan and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available. L. A. Dempsey was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.


**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).



**Extended Data Fig. 1 | Isolation of B cell populations for sequencing studies.** Extended Data Figure 1 **a**, gating strategy used for the isolation of naive B cells (NB), memory B cells (MB), plasmablasts (PC), germinal center centroblasts (CB), and germinal center centrocytes (CC) from human tonsillar lymphocytes using multiparameter fluorescence activated cell sorting (FACS). Lymphocytes were isolated from fresh human tonsils by density gradient centrifugation. Within 24 hours, cells were either sorted by FACS or cryopreserved for cell sorting on a later date (see Methods). Prior to sorting, lymphocytes were labeled with anti-CD20, anti-CD10, anti-CD44, anti-CD27, anti-CD38, and anti-CXCR4 conjugated fluorochromes. DAPI was used to exclude non-viable cells. For isolation of NBs, centroblasts, and centrocytes only, anti-IgD was used in place of anti-CD38 and anti-CD27, and NBs were CD20<sup>+</sup>CD44<sup>+</sup>CD10<sup>-</sup>IgD<sup>+</sup>. Details of antibodies used for cell sorting are listed in Extended data Table 1. SSC: side scatter, FSC: forward scatter.




**Extended Data Fig. 2 | Related to Fig. 1.** Extended Data Figure 2 **a**, ATAC-seq insertion profiles in GCs for 2kb regions centered on gene transcription start sites. Mean profile is shown for genes by quintile of mRNA abundance in GCs. mRNA abundance represented as TPM (transcripts per kilobase million) as estimated by Salmon<sup>58</sup>. **b**, NucleoATAC<sup>42</sup> estimates of nucleosome position and occupancy for gene TSS according to a gene's mRNA abundance quintile in GCs. **c**, MNase-seq reads per million mapped reads (RPM) according to a gene's mRNA abundance quintile in GCs. **d**, NucleoATAC estimates for the position of +1 nucleosome relative to the TSS of genes according to a gene's mRNA abundance quintile in GCB (n=10 biological replicates). **e**, Density plots showing dynamic range of normalized ATAC-seq read counts in ATAC-seq peak-atlas sites across B-cell populations. Promoter elements are located <2kb from a gene TSS. Bars under density plots indicate inter-quantile range. **f**, principal components analysis (PCA) of ATAC-seq insertion counts in gene-distal peak-atlas elements across B cell populations. **g**, Cumulative probability distribution plot of GCB (n=13) vs NB (n=9) gene expression log<sub>2</sub>-fold changes (RNA-seq) for genes assigned to DNA elements that are differentially accessible (FDR < 0.01) or unchanged in GCB (n=10) vs NB (n=6). Gene expression log<sub>2</sub> fold changes are computed using DESeq2<sup>61</sup>. P-values are calculated by Wilcoxon rank-sum test and bars adjacent to p-values indicate the comparison of newly accessible or decommissioned sites to unchanged sites.




Extended Data Fig. 3 | See next page for caption.

**Extended Data Fig. 3 | Related to Fig. 2.** Extended Data Figure 3 **a**, results of *de novo* motif discovery using GCB OCT2 peak summits as input to HOMER<sup>62</sup>. **b**, bar plot showing the fraction of GCB *de novo* accessible or GCB decommissioned sites with or without OCT2 binding. P-values are calculated by Fisher's exact test. **c**, scatter plot showing Bayesian posterior predicted mean chromatin accessibility log<sub>2</sub> fold-changes in GCB (n=10) vs NB (n=6) for sites with 0, 1, 2, or ≥3 OCT2 motifs, and located >5 kb or <5kb of a gene TSS. P-value is computed by ANOVA F-test from observed data, and error bars indicate 99% credible intervals. **d**, bar plot showing sites by their distance to a gene TSS for differentially accessible (FDR < 0.001) or unchanged sites in mouse GCBs (n=10) vs NBs (n=4). P-values are calculated by Fisher's exact test. **e**, scatter plot showing the mean accessibility log<sub>2</sub> fold change in mouse GCBs vs NBs for promoter and distal DNA elements with or without an OCT2 motif. P-value is calculated by ANOVA testing the null hypothesis that the difference in accessibility log<sub>2</sub> fold-changes between promoter and distal elements does not depend on the presence of an OCT2 DNA motif. Error bars indicate 95% CIs. **f**, TF-motif effect size estimates for change in accessibility in mouse GCBs (n=4) vs NBs (n=4). Motif logos represent motif position weight matrices used. **g**, TF-motif effect sizes for histone H3K4me1 log<sub>2</sub> fold-changes in mouse GCBs (n=4) relative to NBs (n=4); **h**, for histone H3K27ac log<sub>2</sub> fold-changes in mouse GCBs (n=4) vs NBs (n=4); and **i**, for gene expression log<sub>2</sub> fold-changes in mouse GCBs (n=7) vs NBs (n=6). Error bars represent 95% CIs. **j**, immuno blot for OCAB and OCT2 in human NBs and GCBs. This blot was repeated independently with similar results for two biological replicate samples.




Extended Data Fig. 4 | See next page for caption.

**Extended Data Fig. 4 | Related to Fig. 3.** Extended Data Figure 4 **a**, results of *de novo* motif discovery as reported by HOMER for OCT2 ChIP-seq NBs. **b**, bar plots comparing the genomic localization of indirect, pre-positioned, and GCB *de novo* OCT2 sites. **c**, genome browser plot of OCT2 ChIP-seq in NBs and GCBs, OCAB ChIP-seq in GCBs, and ATAC-seq in NBs and CBs. ChIP-seq tracks show fold enrichment/input and each sample is plotted using identical Y scale. ATAC-seq tracks were normalized to number of reads B cell DNA elements and use identical Y scales across samples. **d**, density plots showing the mean distance to the nearest GCB *de novo* OCT2 site for pre-positioned OCT2 sites (red) or random sample of DNA elements in B cells (expectation, gray). Statistics were computed by resampling using the regioneR package in R. **e**, Box plot comparing cluster coreness for differentially accessible or unchanged sites in GCBs (n=10) vs NBs (n=6). Cluster coreness of sites is computed using a graph of peak-peak distances with clusters defined by infonet community detection. P-values are computed by Mann-Whitney U test. **f**, ATAC-seq insertion profiles in GCB and NB centered on the OCT2 motif in pre-positioned and GCB *de novo* OCT2 sites. **g**, boxplot comparing H3k27ac activating mark and H3K27me3 repressive mark in NB and GCB at OCT2 pre-positioned sites. P-values are calculated by Mann-Whitney U test. **h**, read density heat maps showing ChIP-seq enrichment/input for OCT2, OCAB, and histones H3K4me1 and H3K27ac. ATAC-seq heatmaps show log<sub>2</sub> (GCB / NB) insertions. Box plots show center line as median, box limits as upper and lower quartiles, whiskers as minimum and maximum values within 1.5 x inter-quartile range of 1<sup>st</sup> and 3<sup>rd</sup> quartile, and notches as approximate 95% CI of the median.




**Extended Data Fig. 5 | Related to Fig. 4.** Extended Data Figure 5 **a**, comparison of motif position weight matrices as defined from *de novo* motif discovery of pre-positioned and GCB *de novo* sites. Motif divergence was computed using the R package motifDiverge. Significant divergence indicated by \*. **b**, results of *de novo* motif discovery as reported by HOMER for OCT2 ChIP-seq and OCAB ChIP-seq in GCBs. **c**, barplot showing the fraction of sites with OCAB recruitment in mouse GCBs and comparing sites with OCT2 direct binding in murine splenic B cells and sites in which OCT2 is absent. CHIP-seq data for OCT2 and OCAB were retrieved from [GSE142040](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE142040). P-value by Fisher's exact test. **d**, boxplots of log<sub>2</sub> fold changes in mouse GCB (n = 10) vs NB (n = 4) chromatin accessibility, mouse GCB (n = 2) vs NB (n = 2) histone H3K27ac, and mouse GCB (n = 2) vs NB (n = 2) histone H3K4me1 and comparing OCT2 direct sites in splenic B cells that recruit OCAB in GCBs (OCT2-OCAB sites) with all other accessible sites. P-values by Welch t-test. Box plots show center line as median, box limits as upper and lower quartiles, whiskers as minimum and maximum values within 1.5 x inter-quartile range of 1<sup>st</sup> and 3<sup>rd</sup> quartile, and notches as approximate 95% CI of the median.




Extended Data Fig. 6 | See next page for caption.


**Extended Data Fig. 6 | Related to Fig. 4.** Extended Data Figure 6 **a**, illustration of the strategy for OCAB depletion (OCABi) in GCB-derived cells. Viable, GFP+ OCI-Ly7 and SUDHL4 cells expressing dCas9-KRAB were isolated by FACS 72 hours after transduction with sgRNA and GFP. **b**, chromatin accessibility PCA of B cells and cell lines using DAEs across B cell phenotypes. **c**, gene expression PCA of B cells and cell lines using differentially expressed genes across B cell phenotypes (FDR < 0.001). **d**, plot showing the fraction of GFP+ viable OCI-Ly7 or SUDHL4 (**e**) cells after transduction with control sgRNAs (n = 6) or sgRNAs targeting OCAB (OCABi, n = 15). Shaded area shows 95% CI of the mean. **f**, bar plot showing OCAB transcript abundance (TPM)<sup>51</sup> in OCABi (n = 6 replicate experiments) vs control (n = 6) OCI-Ly7 cells, and OCABi (n = 2) vs control (n = 2) SUDHL4 cells. P-values are calculated by Welch t-test and error bars show standard error of the mean. **g**, OCAB expression relative to HPRT in control (n = 3) and OCABi (n = 3) OCI-Ly7 cells by qPCR. P-values are calculated by Welch t-test and error bars show standard error of the mean. **h**, unsupervised hierarchical clustering dendrogram based on *Pearson correlation distance* of OCABi and control OCI-Ly7 and SUDHL4 chromatin accessibility and gene expression (**i**). **j**, scatter plot showing chromatin accessibility of OCABi and control OCI-Ly7 or SUDHL4 (**k**) cells projected onto PCs from primary B cell chromatin accessibility PCA (Fig. 4I). **l**, scatter plot showing OCI-Ly7 OCABi and control or SUDHL4 OCABi and control (**m**) gene expression projected onto PCs from primary B cells (Fig. 4K). **n**, illustration showing trajectories in B-cell development during the humoral immune response. Relative position of cell types and length of arcs is defined from PCA of mean accessibility signal for each cell type.



**Extended Data Fig. 7 | Related to Fig. 5.** Extended Data Figure 7 **a**, experimental design for forced expression of *Pou2af1*, the gene encoding OCAB in mouse. Splenic B cells from  $n=5$  mice were stimulated with LPS *ex vivo* and transduced with a GFP vector containing *Pou2af1* (mOCAB) or GFP only (control). **b**, expression of *Pou2af1* in mOCAB ( $n=5$ ) and control ( $n=5$ ) B cells. Expression levels were measured by qPCR using cDNA generated from total RNA of GFP+ viable cells and normalized to that of *Hprt1*, calculated by the delta-delta Ct method ( $2^{-\Delta\Delta Ct}$ ) and represented as a fold change over the mean expression in control cells. The expression of each gene was measured in triplicate across 5 replicates. P-values are calculated by Welch's t test and error bars show standard error of the mean.




**Extended Data Fig. 8 | Related to Fig. 6.** Extended Data Figure 8 **a**, pie chart showing the fraction of H3K27ac HiChIP loops that form enhancer-promoter (E-P) contacts for loops anchored by an OCAB-OCT2 sites (left) or not anchored by an OCAB-OCT2 site (right). The inner circle represents the fraction of loops that form E-P contacts, and the outer circle distinguishes whether the promoter belongs to a gene whose expression is differentially increased, decreased, or unchanged in GCB vs NB. \*Indicates significantly greater fraction for OCT2-OCAB loops compared to loops not anchored by OCT2-OCAB. P-values by Fisher's exact test and \* indicates FDR-corrected  $p < 10^{-5}$ . **b**, effect estimates for the contribution of enhancer activity score to a gene's change in expression in biological replicate GCBs ( $n=6$ ) relative to NBs ( $n=6$ ) for enhancers with direct binding present or direct binding absent for the indicated TF. Effect sizes were computed from a linear regression of GCB / NB expression log<sub>2</sub> fold-change on the total enhancer activity score per gene for enhancers with and without TF direct binding, and error bars show 95% CI for mean effect estimate. Activity-contact score was computed from OCI-Ly7 H3K27ac HiChIP ( $n=2$  biological replicates), GCB H3K27ac ChIP-seq ( $n=4$  biological replicates), and using the 76237 ATAC-seq DNA elements identified in B cells. **c**, APA plots showing aggregate contact enrichment vs local background in Control and OCABi OCI-Ly7 cells and the difference in contact enrichment between OCABi and Control. Plots centered on anchor mid-points of called loops that were sensitive to OCAB depletion at 1% FDR.



Extended Data Fig. 9 | See next page for caption.

**Extended Data Fig. 9 | Related to Fig. 7.** Extended Data Figure 9 **a**, Box plots of cluster coreness comparing DNA elements with OCT2-OCAB ( $n = 6768$ ) or without OCT2-OCAB ( $n = 69469$ ). P-values are calculated by Mann-Whitney U test. Box plots show center line as median, box limits as upper and lower quartiles, and whiskers as minimum and maximum values within 1.5 x inter-quartile range of 1<sup>st</sup> and 3<sup>rd</sup> quartile. **b**, box plots showing log<sub>2</sub> fold change in histone H3K27ac ChIP-seq enrichment in GCBs ( $n = 4$ ) vs NBs ( $n = 4$ ) for clustered sites with or without OCT2-OCAB binding. P-value is computed by Welch's *t*-test. **c**, genome browser plot of the BCL6 locus. **d**, Venn diagram of super-enhancers (SEs) in NBs and GCBs. **e**, plot of enhancers and SEs (red points) in GCBs. **f**, empirical cumulative distribution plot of contact distance for EP loops. P-value is calculated by Mann-Whitney U test. **g**, APA plots of GC-activated SE loops in control and OCABi OCI-Ly7 cells. **h**, bar plot of H3K27ac HiChIP APA scores for 621 GC-activated SE loops in OCI-Ly7 control ( $n = 3$ ) or OCABi ( $n = 2$ ) cells. P-value is calculated by *t*-test and error bars show standard error of the mean. **i**, GSEA enrichment plot using expression change in OCABi vs control for target genes of GC-activated SEs. **j**, Scatter plot showing per-gene aggregate HiChIP contact enrichment log<sub>2</sub> fold changes in OCI-Ly7 OCABi vs Control. **k**, Scatter plot of aggregate H3K27ac ChIP-seq log<sub>2</sub> fold changes in GCBs vs NBs for sites within a SE. Red and blue points indicate SEs above the 90<sup>th</sup> and below the 10<sup>th</sup> percentile, respectively. **l**, Super-enhancer analysis using the ROSE method with GCB OCT2 ChIP-seq signal over stitched GCB OCT2 ChIP-seq peaks. **m**, scatter plot showing the number of called H3K27ac Hi-ChIP enhancer-promoter loops per gene promoter for genes expressed in OCI-Ly7 cells.



**Extended Data Fig. 10 | Related to Fig. 8.** Extended Data Figure 10 **a**, genome browser plot of a region on chromosome 3 containing BCL6 and adjacent super-enhancer. OCT2-OCAB sites are shown with Pre-positioned OCT2 sites in red and GCB *de novo* OCT2 sites in black. H3K27ac HiChIP called loops in OCI-Ly7 cells. Plot showing NB and GCB 4C contact enrichment representing interactions with the 4C anchor, located at the BCL6 TSS. Bar plot showing differential 4C contact enrichment with bars labeled according to FDR for differential contacts. Normalized and differential contact enrichment computed using 4C-ker<sup>43</sup> and DESeq2<sup>61</sup>.

## Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	For RNA-seq, ATAC-seq, and Hi-ChIP studies, we required at least 2 biological replicates per condition
Data exclusions	Data that did not meet quality control requirements were excluded prior to analysis.
Replication	Experimental findings presented in this study were reproducible across 2 or more independent experiments.
Randomization	For all experiments performed, treatment and control samples were performed in parallel from the same initial population of cells. Randomization was not applicable.
Blinding	There was no intervention our outcome assessed as part of this study, and blinding was not relevant.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

### Methods

n/a	Involved in the study	n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies	<input type="checkbox"/>	<input checked="" type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines	<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology	<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Human research participants		
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data		
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern		

## Antibodies

Antibodies used	Marker Fluorochrome Lot# Manufacturer Dilution CD20 Pacific Blue 2H7 BioLegend 0.01 CD44 APC-H7 G44-26 BD 0.025 CD10 PE-Cy7 HI10a BD 0.05 CD38 FITC NA Cytognos 0.03 CD27 APC L128 BD 0.03 CD184 / CXCR4 PE NA BD 0.1 IgD PE NA Miltenyi 0.03
Validation	OCT2 (ChIP-seq): <a href="https://www.scbt.com/p/oct-2-antibody-pt2">https://www.scbt.com/p/oct-2-antibody-pt2</a> , OCAB(ChIP-seq): <a href="https://www.scbt.com/p/bob-1-antibody-6f10">https://www.scbt.com/p/bob-1-antibody-6f10</a> , OCT2 (immunoblot): <a href="http://tools.thermofisher.com/content/sfs/brochures/D12603~.pdf">http://tools.thermofisher.com/content/sfs/brochures/D12603~.pdf</a> , OCAB(immunoblot): <a href="https://www.cellsignal.com/products/primary-antibodies/bob-1-obf-1-antibody/33483?Ntk=Products&amp;site-search-type=Products&amp;N=4294956287&amp;Ntt=33483s&amp;fromPage=plp&amp;_requestid=894440">https://www.cellsignal.com/products/primary-antibodies/bob-1-obf-1-antibody/33483?Ntk=Products&amp;site-search-type=Products&amp;N=4294956287&amp;Ntt=33483s&amp;fromPage=plp&amp;_requestid=894440</a>

## Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)	OCI-Ly7 was obtained from Ontario Cancer Institute in June 2011. SUDHL4 cells were obtained from ATCC (CRL-2957, ATCC), and HEK293T were obtained from ATCC (CRL-3216, ATCC).
Authentication	OCI-Ly7, SUDHL4, and HEK293T were authenticated by STR.

Mycoplasma contamination	Results of annual mycoplasma testing were negative for all cell lines used in this study.
Commonly misidentified lines (See <a href="#">ICLAC</a> register)	No commonly misidentified cell lines were used in this study.

## Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals	2 female and 3 male C57BL/6J mice aged 2-4 months.
Wild animals	No wild animals were used in this study.
Field-collected samples	No field collected samples were used in this study.
Ethics oversight	Animal studies were approved by Weill Cornell Medicine's Institutional Animal Care and Use Committee (IACUC).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics	<i>Describe the covariate-relevant population characteristics of the human research participants (e.g. age, gender, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural &amp; social sciences study design questions and have nothing to add here, write "See above."</i>
Recruitment	<i>Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.</i>
Ethics oversight	Use of human tissue was approved by Weill Cornell Medicine Institutional Review Board.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## ChIP-seq

### Data deposition

- Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).
- Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links <i>May remain private before publication.</i>	<a href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE159314">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE159314</a>
Files in database submission	Raw fastq files (via linked SRA), bedGraph files, bed files.
Genome browser session (e.g. <a href="#">UCSC</a> )	<a href="https://genome.ucsc.edu/s/bassounds/Doane_et_al">https://genome.ucsc.edu/s/bassounds/Doane_et_al</a>

### Methodology

Replicates	Biological replicates were performed when sufficient material was obtainable to do so (all ATAC-seq data and HiChIP data).																														
Sequencing depth	<table border="1"> <thead> <tr> <th>sample</th> <th>reads (M)</th> <th>unique filtered reads (M)</th> <th>read_length</th> <th>format</th> </tr> </thead> <tbody> <tr> <td>GCB_Input</td> <td>43.6</td> <td>32.8</td> <td>75bp</td> <td>single-end</td> </tr> <tr> <td>GCB_OCAB</td> <td>44</td> <td>31.1</td> <td>75bp</td> <td>single-end</td> </tr> <tr> <td>GCB_OCT2</td> <td>25.3</td> <td>11.1</td> <td>75bp</td> <td>single-end</td> </tr> <tr> <td>NB_Input</td> <td>55.7</td> <td>42.1</td> <td>75bp</td> <td>single-end</td> </tr> <tr> <td>NB_OCT2</td> <td>32.7</td> <td>14.1</td> <td>75bp</td> <td>single-end</td> </tr> </tbody> </table>	sample	reads (M)	unique filtered reads (M)	read_length	format	GCB_Input	43.6	32.8	75bp	single-end	GCB_OCAB	44	31.1	75bp	single-end	GCB_OCT2	25.3	11.1	75bp	single-end	NB_Input	55.7	42.1	75bp	single-end	NB_OCT2	32.7	14.1	75bp	single-end
sample	reads (M)	unique filtered reads (M)	read_length	format																											
GCB_Input	43.6	32.8	75bp	single-end																											
GCB_OCAB	44	31.1	75bp	single-end																											
GCB_OCT2	25.3	11.1	75bp	single-end																											
NB_Input	55.7	42.1	75bp	single-end																											
NB_OCT2	32.7	14.1	75bp	single-end																											
Antibodies	OCT2 (ChIP-seq): <a href="https://www.scbt.com/p/oct-2-antibody-pt2">https://www.scbt.com/p/oct-2-antibody-pt2</a> , OCAB(ChIP-seq): <a href="https://www.scbt.com/p/bob-1-antibody-6f10">https://www.scbt.com/p/bob-1-antibody-6f10</a> , OCT2																														
Peak calling parameters	macs2 callpeak -t <sample> -c <input> -q 0.001 -B --call-summits --SPMR																														
Data quality	The normalized strand correlation (NSC) was >1 and the relative strand correlation (RSC) was > 1 for all samples, as recommended as primary ChIP-seq data quality metrics by ENCODE. <table border="1"> <thead> <tr> <th>Sample</th> <th>Estimated_Fragment_Length_bp</th> <th>NSC</th> <th>RSC</th> </tr> </thead> <tbody> <tr> <td>GCB_OCAB</td> <td>180</td> <td>1.057772</td> <td>1.357375</td> </tr> <tr> <td>GCB_OCT2</td> <td>165</td> <td>1.179263</td> <td>1.653146</td> </tr> <tr> <td>NB_OCT2</td> <td>180</td> <td>1.098637</td> <td>1.718416</td> </tr> </tbody> </table>	Sample	Estimated_Fragment_Length_bp	NSC	RSC	GCB_OCAB	180	1.057772	1.357375	GCB_OCT2	165	1.179263	1.653146	NB_OCT2	180	1.098637	1.718416														
Sample	Estimated_Fragment_Length_bp	NSC	RSC																												
GCB_OCAB	180	1.057772	1.357375																												
GCB_OCT2	165	1.179263	1.653146																												
NB_OCT2	180	1.098637	1.718416																												

## Flow Cytometry

---

### Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

### Methodology

Sample preparation

Lymphocytes were isolated from fresh human tonsils by density gradient centrifugation and stained overnight before sorting.

Instrument

BD Influx sorter, Weill Cornell Medicine Flow Cytometry Core

Software

FlowJo

Cell population abundance

Examples of cell population abundance have been provided in Extended data figures in all cases.

Gating strategy

Examples of gating strategies have been provided in Extended data figures in all cases.

- Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.